Financial Report September 30, 2023

Contents

Independent Auditor's Report	1 – 3
Management's Discussion and Analysis (Unaudited)	4 – 13
Financial Statements:	
Statement of Net Position	14 – 15
Statement of Revenues, Expenses and Changes in Net Position	16
Statement of Cash Flows	17 – 18
Statement of Fiduciary Net Position	19
Statement of Changes in Fiduciary Net Position	20
Notes to Financial Statements	21 – 57
Required Supplementary Information (Unaudited):	
Schedule of Changes in Net Pension Liability – Halifax Pension Plan	58 – 59
Schedule of Funding Progress – Halifax Pension Plan	60
Schedule of Actuarially Determined Contributions – Halifax Pension Plan	61
Note to Required Supplementary Information – Halifax Pension Plan	62
Schedule of Changes in Total Retiree HRA Plan Liability and Related Ratios	63
Schedule of Changes in Total Retiree Medical Plan Liability and Related Ratios	64
Other Supplementary Information:	
Schedule of Net Position – Obligated Group	65 - 66
Schedule of Revenues, Expenses and Changes in Net Position – Obligated Group	67
Note to Schedules – Obligated Group	68
Condensed Combining Schedule of Revenues, Expenses and Changes in Net Position –	
Florida Hospital Uniform Reporting System	69



Independent Auditor's Report

RSM US LLP

Honorable Commissioners of the Board Halifax Hospital Medical Center d/b/a Halifax Health

Report on the Audit of the Financial Statements

Opinions

We have audited the financial statements of the business-type activities and fiduciary activities of Halifax Hospital Medical Center d/b/a Halifax Health (Halifax Health), as of and for the year ended September 30, 2023, and the related notes to the financial statements, which collectively comprise Halifax Health's basic financial statements as listed in the table of contents.

In our opinion, the accompanying financial statements referred to above present fairly, in all material respects, the respective financial position of the business-type activities and fiduciary activities of Halifax Health as of September 30, 2023, and the respective changes in financial position and cash flows thereof for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinions

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Halifax Health and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

We did not audit the basic financial statements of Halifax Health's fiduciary activities as of and for the year ended September 30, 2023, as presented on pages 19-20, which represent 100% of the total assets and additions and deductions of the fiduciary activities. The basic financial statements of Halifax Health's fiduciary activities was audited by other auditors, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for Halifax Health's fiduciary activities, is based solely on the report of the other auditors.

Emphasis of Matter

As explained in Note 2 to the financial statements, Halifax Health adopted Governmental Accounting Standards Board (GASB) Statement No. 96, *Subscription-Based Information Technology Arrangements*, during the year ended September 30, 2023, which is applied retroactively by restating balances in the financial statements as of October 1, 2022. Our opinion is not modified with respect to this matter.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

THE POWER OF BEING UNDERSTOOD AUDIT | TAX | CONSULTING

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Halifax Health's ability to continue as a going concern for 12 months beyond the financial statement date, including any currently known information that may raise substantial doubt shortly thereafter.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of Halifax Health's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about Halifax Health's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Required Supplementary Information

Accounting principles generally accepted in the United States of America require that Management's Discussion and Analysis on pages 4-13 and the required supplementary information on pages 58-64 be presented to supplement the basic financial statements. Such information is the responsibility of management and, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements that collectively comprise Halifax Health's basic financial statements. The accompanying Obligated Group and Florida Hospital Uniform Reporting System (FHURS) financial information on pages 65-69 is presented for purposes of additional analysis and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the Obligated Group and FHURS financial information is fairly stated, in all material respects, in relation to the basic financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated January 25, 2024 on our consideration of Halifax Health's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Halifax Health's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Halifax Health's internal control over financial reporting and compliance.

RSM US LLP

Davenport, Iowa January 25, 2024

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

INTRODUCTION

This section of the Halifax Hospital Medical Center (the "Medical Center") d/b/a Halifax Health's annual financial report provides an overview of the organization and management's discussion and analysis of financial performance and results for the fiscal year ended September 30, 2023. This analysis should be read in conjunction with the accompanying basic financial statements.

The Medical Center was originally created in 1925 under the name Halifax Hospital District by Chapter 112.72, Laws of Florida, 1925, as amended ("Enabling Act"). The Medical Center's Board of Commissioners (the "Board") is empowered to levy ad valorem taxes for operating expenses, capital outlays, and other purposes. Pursuant to the Enabling Act, the Medical Center has all the powers of a body corporate, including, but not limited to, the power to establish, construct, operate, and maintain such hospitals, medical facilities, and health care facilities and services for the preservation of the public health, for the public good, and for the use of the public; to enter into contracts; to borrow money; to establish for-profit and not-for-profit corporations; to acquire, purchase, hold, lease, and convey real and personal property; and of eminent domain.

After an amendment in 2019, the Enabling Act further authorizes the Medical Center to establish, own, construct, equip, operate, manage, and maintain hospitals and facilities and provide services within and beyond the boundaries of the geographic taxing district in the counties of Brevard, Flagler, Lake, and Volusia, as well as allow the continuance of hospice care services throughout the State of Florida. This is as long as proceeds from ad valorem taxes and non-ad valorem special assessments outside the boundaries of the taxing district are not used.

The Medical Center owns and operates three inpatient hospital facilities with a combined 673 beds under one license from the Agency for Health Care Administration ("AHCA"). The main campus of the Medical Center, located in Daytona Beach, includes a Level III neonatal intensive care center and a Level II state-certified trauma center, offering open-heart surgery, neurosurgery, inpatient rehabilitation and other specialty inpatient and outpatient services. The Port Orange campus, located 10 miles south of the main campus, is a community hospital providing a broad range of services to the residents of Port Orange and southeast Volusia County. The Halifax Behavioral Services ("HBS") campus, two miles north of the main campus, provides inpatient and outpatient child, adolescent, and adult psychiatric services. In addition to its inpatient facilities, the Medical Center owns and operates outpatient centers in Daytona Beach, Port Orange, Ormond Beach, Palm Coast, New Smyrna Beach, and Deland.

Further, the Medical Center of Deltona ("MCD") was established and opened in February 2020. MCD is a 43-bed hospital, separately licensed by AHCA, that provides the Deltona community with a hospital and high-quality medical care. In addition, MCD also owns and operates the outpatient centers located in Deltona.

The licensed beds by location are set forth in the table below:

Licensed Beds by Location

Main campus:	
Inpatient hospital	523
Inpatient rehabilitation	40
Port Orange campus	80
Medical Center of Deltona	43
HBS campus	30
Total	716

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

The Medical Center has established not-for-profit corporations (the "component units" or the "affiliates") to assist in carrying out its purpose to provide health care and related services to the community. The component units are legally separate organizations that were established to provide administrative and other services for and on behalf of the Medical Center. The component units of the Medical Center are:

- East Volusia Health Services, Inc. ("EVHS")
- HH Holdings, Inc. ("Holdings")
- Halifax Healthcare Systems, Inc. ("HHCSI")
- Halifax Healthy Families Corporation d/b/a Healthy Communities ("Healthy Communities")
- Halifax Staffing, Inc. ("Staffing")
- Patient Business & Financial Services, Inc. ("PBFS")
- Halifax Hospice, Inc. d/b/a Halifax Health Hospice ("Hospice")
- Halifax Management System, Inc. ("HMS")
- Halifax Medical Center Foundation, Inc. ("Foundation")
- Medical Center of Deltona, Inc. ("MCD")
- Volusia Health Ventures, Inc. d/b/a Volusia Health Network ("VHN")

These corporations are considered blended component units of the Medical Center and their financial results are blended with the Medical Center in the accompanying financial statements. See Note 1 of the audited financial statements for a description of each component unit and combining schedules. The Medical Center, together with all of its component units, is referred to as "Halifax Health."

OVERVIEW OF THE FINANCIAL STATEMENTS

This annual financial report includes the independent auditor's report, management's discussion and analysis, and the basic financial statements of Halifax Health. The basic financial statements are intended to describe the net position, results of operations, sources and uses of cash, and the capital structure of Halifax Health. Fiduciary fund statements for the pension trust fund are also provided as part of the basic financial statements. The basic financial statements include notes providing detailed information for select accounts and transactions.

In addition to the aforementioned content, the annual financial report includes required supplementary information composed of unaudited schedules of changes in net pension liability, funding progress, and actuarially determined contributions for the Halifax Pension Plan, and schedules of funding progress for the Halifax Health Retiree HRA and for the Halifax Retiree Medical postemployment benefit plans.

Schedules of net position and revenues, expenses, and changes in net position for the Obligated Group are included as additional (supplementary) information. The members of the Obligated Group are the Medical Center and Holdings. In accordance with generally accepted accounting principles, certain component units are blended with the accounts of the Medical Center in the Obligated Group financial information, including EVHS, Staffing, HHCSI and PBFS.

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

NET POSITION AND CHANGES IN NET POSITION

Net position is an indicator of the financial health of an organization. Increases in net position over time indicate that the financial condition is improving while decreases in net position over time signify a declining financial condition. A comparative summary of the financial condition of Halifax Health is presented below:

Condensed Statements of Net Position (In Thousands)

	September 30,			
		2023		2022
Current assets	\$	637,378	\$	621,135
Assets whose use is limited, noncurrent		35,055		34,556
Capital and right to use assets, net		478,943		429,658
Other noncurrent assets and deferred outflows		224,723		200,960
Total assets and deferred outflows	\$	1,376,099	\$	1,286,309
Current liabilities	\$	188,701	\$	143,695
Long-term debt and premium on long-term debt, net		447,684		458,241
Noncurrent liabilities and deferred inflows		262,151		263,161
Total liabilities and deferred inflows		898,536		865,097
Net investment in capital assets		38,843		(5,806)
Restricted net position		5,671		5,671
Unrestricted net position		433,049		421,347
Total net position		477,563		421,212
Total liabilities, deferred inflows and net position	\$	1,376,099	\$	1,286,309

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

The statement of revenues, expenses and changes in net position measures the annual operating success of the organization and can be used to determine whether costs have been recovered through operating revenue sources. Following is a comparative summary of the operations of Halifax Health.

Condensed Statements of Revenues and Expenses (In Thousands)

	September 30,			30,
		2023		2022
Operating revenue Operating expenses	\$	786,457 (747,524)	\$	704,123 (683,295)
Income from operations		38,933		20,828
Nonoperating revenues (expenses), net		5,418		(28,216)
Contributions		12,000		-
Increase (decrease) in net position	\$	56,351	\$	(7,388)

MANAGEMENT'S DISCUSSION OF RECENT FINANCIAL PERFORMANCE

COVID-19 Pandemic

The Medical Center's operations and financial condition were significantly impacted by the emergence of a novel coronavirus ("COVID-19") which has evolved into a global pandemic. On March 13, 2020, President Trump declared a national emergency in response to the COVID-19 pandemic. Shortly thereafter, President Trump and the Centers for Medicare and Medicaid Services ("CMS") recommended health care providers limit all "non-essential" elective medical and surgical procedures. On March 20, 2020, Florida Governor DeSantis issued Executive Order 20-72, which prohibited "any medically unnecessary, non-urgent or non-emergency procedure or surgery which, if delayed, does not place a patient's immediate health, safety, or wellbeing at risk". The Medical Center immediately complied with Executive Order 20-72 by canceling all elective procedures and began preparing for an anticipated surge in COVID-19 patients.

The financial impact of the COVID-19 pandemic has been driven by lost revenue, due to sharp declines in patient volume resulting from Executive Order 20-72, and increased expenses due to an increased need for personal protective equipment for caregivers and visitors, and materials and staffing necessary for COVID-19 testing (i.e., swabs, collection kits, reagents, etc.). Management estimates that the effect of the COVID-19 pandemic has resulted in increases in operating expenses of \$36.9 million and \$55.3 million for fiscal years 2023 and 2022, respectively.

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

Total assets and deferred outflows of Halifax Health increased \$89.8 million from September 30, 2022. Current assets of Halifax Health increased \$16.2 million from fiscal year 2022 primarily as a result a increase in investments of \$28.3 million partially offset by a decrease in cash and cash equivalents of \$22.0 million. Other current assets decreased \$4.3 million which was mostly offset by the increase in inventories of \$3.0 million. Accounts receivable increased by \$12.0 million due to increased patient volumes. Capital and right to use assets, net of accumulated depreciation increased \$49.3 million from 2022 due to purchases of capital assets of \$64.1 million and the addition of \$20.5 million in right to use assets recorded as a result of the implementation of GASB Statement No. 96, *Subscription-Based Information Technology Arrangements* ("GASB No. 96"), offset by depreciation and amortization of \$34.7 million. Other noncurrent assets and deferred outflows increased \$23.8 million from 2022 primarily due to the increases in deferred outflows related to the pension plan of \$27.8 million and an increase of other assets of \$4.8 million, offset by decreases in the interest rate swap of \$5.4 million, the decrease of the investment in securities loan agreement of \$1.9 million.

Total liabilities and deferred inflows of Halifax Health increased \$33.4 million from September 30, 2022. Current liabilities increased \$45.0 million primarily as a result of an increase in accounts payable of \$29.7 million and an increase in accrued payroll of \$8.8 million.

Long-term debt, excluding current portion due, decreased approximately \$10.6 million from September 30, 2022 primarily as a result of the principal payments made on the bonds. As of September 30, 2023, the Medical Center's outstanding bonds (Series 2008, Series 2015, and Series 2016) were rated A- by Standard & Poor's, and A- by Fitch Ratings with a stable outlook.

The decrease in noncurrent liabilities and deferred inflows of Halifax Health of \$1.1 million from September 30, 2022 is primarily due to the decrease in the payable to Shands of \$12.0 million, a decrease in long-term value of interest rate swap of \$5.4 million, decrease of long-term lease liabilities under GASB No. 87, less current portion of \$1.7 million, an increase in the net pension liability of \$34.8 million, offset by the decrease to deferred inflows related to pension of \$15.1 million.

The net position of Halifax Health at September 30, 2023, was \$477.6 million, an increase of \$56.4 million from September 30, 2022.

Operating Revenues

The increase in operating revenues of \$82.3 million over 2022 of Halifax Health is primarily the result of increased volumes in inpatient admissions, emergency department visits, vascular, cardiology, neurosurgery and hospice service lines. Halifax Health continues to expand the quality and continuum of services that it provides to the community.

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

Utilization statistics for the years ended September 30, 2023 and 2022 are as follows:

Halifax Health Utilization Statistics

	Septembe	er 30,
	2023	2022
Medical Center Activity:		
Admissions	25,795	23,672
Patient days	149,083	135,721
Average daily census	408	372
Total outpatient visits	282,807	280,820
Observation patient day equivalents	10,088	13,739
Medical Center of Deltona Activity:		
Admissions	2,006	1,524
Patient days	7,018	6,270
Average daily census	19	17
Total outpatient visits	20,207	18,569
Observation patient day equivalents	1,951	2,011
Hospice Activity:		
Hospice patient days	255,140	228,631

Halifax Health's inpatient admissions for 2023 increased by 2,605 admissions compared to 2022, and patient days for 2023 increased by 14,110 (11.1%) compared to 2022. The increase in patient days led to an increase in the average daily census by 39 patients per day from the prior year. Outpatient visits for 2023 increased by 3,625 compared to 2022.

Operating Expenses

Total operating expenses of Halifax Health increased by \$64.2 million in fiscal year 2023 compared to fiscal year 2022 primarily due to an increase in salaries of \$54.2 million, an increase in supplies of \$16.6 million, an increase in depreciation and amortization expense of \$4.9 million offset by a decrease in purchased services of \$13.1 million.

Halifax Health also incurs expenses related to ad valorem taxes levied. These expenses include payments to Volusia County and the cities of Daytona Beach, Ormond Beach, Holly Hill, South Daytona and Port Orange (tax collector and appraiser commissions, Medicaid matching funds, and redevelopment taxes) and the costs of non-hospital community health services (physician services, community clinics, prescription drugs, medical supplies, etc.). Ad valorem tax-related expenses were substantially the same from 2023 to 2022.

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

Nonoperating Revenues, Expenses, Gains and Losses

Investment income increased \$35.7 million in fiscal year 2023 compared to fiscal year 2022 as a result of favorable performance of the equity markets. Investment income for the year ended September 30, 2023 includes a favorable change in unrealized gains and losses, net of approximately \$11.4 million.

KEY FINANCIAL INDICATORS

The following represents a summary of key financial indicators of Halifax Health:

Key Financial Indicators

	September 30,			30,
		2023		2022
Total margin		5.5%		(1.1)%
Days cash on hand		276		288
Unrestricted cash to long-term debt		114.8%		110.6%
Long-term debt to capitalization		49.9%		53.4%
Total net patient service revenue, before provision for bad				
debts (in millions)	\$	793.9	\$	719.7

The total margin increased to 5.5% in fiscal year 2023 due to an increase in operating revenues and nonoperating revenues primarily related to investment income compared to fiscal year 2022. The number of days cash on hand, which includes unrestricted cash, investments and board designated assets whose use is limited, decreased from 288 days at September 30, 2022 to 276 days at September 30, 2023, due primarily to increased average expense per day.

Total net patient service revenue, before provision for bad debts, increased \$74.2 million from 2022 as a result of increased volumes in inpatient admissions, emergency department visits, vascular, cardiology, neurosurgery and hospice service lines.

COMMUNITY BENEFIT

Halifax Health provides a continuum of health care services to the community and is involved in numerous outreach programs that help meet the public health needs of the community. Halifax Health provided an estimated \$46.3 million in community benefits during fiscal year 2023, which is comprised of amounts paid for community health and wellness services and the cost of uncompensated care, calculated by multiplying the cost-to-charge ratio times to the total amount of uncompensated care deductions from gross revenue.

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

The table below shows the sources and uses of the ad valorem tax revenues of Halifax Health, which includes community benefits:

SCHEDULE OF USES OF PROPERTY TAXES

(in thousands)

	September 30,			30,
		2023		2022
Gross property tax levy	\$	20,640	\$	20,055
Tax discounts and uncollectible taxes		(612)		(630)
Net property taxes collected		20,028		19,425
Amounts paid to Volusia County and Cities: Tax collector and appraiser commissions Volusia County Medicaid matching assessment Redevelopment taxes paid to Cities Subtotal		(453) (2,794) (1,179) (4,426)		(656) (3,011) (1,081) (4,748)
Net taxes available for community health, wellness and readiness		15,602		14,677
Amounts paid for community health and wellness services: Preventive health services (clinics, Healthy Kids, etc.) Physician services Trauma services Pediatric and neonatal intensive care services Child and adolescent behavioral services Subtotal		(229) (10,336) (6,407) (1,750) (370) (19,092)		(187) (10,002) (5,597) (478) (460) (16,724)
Deficiency of net taxes available to fund hospital operating expenses		(3,490)		(2,047)
Uncompensated care provided by Halifax Health, at cost: Halifax Health patients at facilities within the Halifax Health tax district Non Halifax Health taxing district patients and other write-offs Subtotal		(27,240) (15,592) (42,832)		(29,439) (13,907) (43,346)
Total deficiency of net taxes available to fund hospital operating expenses and uncompensated care provided by Halifax Health, <i>at cost</i>	\$	(46,322)	\$	(45,393)

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

RISK FACTORS

The health care industry is highly dependent on several factors that could have a significant effect on the future operations and financial condition of Halifax Health. These factors include, but are not limited to, competition, state and federal regulatory authorities, Medicare and Medicaid laws and regulations, health care reform initiatives, environmental laws, advances in technology, changes in demand for health care services, demographic changes, and managed care contract terms and conditions.

As of the date of this report, the following known facts, decisions, or conditions may have a significant effect on net position or the results of operations:

- Salaries in the health care industry continue to be very competitive due to increased costs of
 attracting and retaining quality physicians, registered nurses, and other health care professionals.
 The COVID-19 pandemic has made attracting and retaining clinical staff more difficult and has
 caused health care providers including Halifax Health to utilize contracted clinical services, resulting
 in increased costs. During the year ended September 30, 2023, the Medical Center incurred
 increased costs for internal clinical staffing and contract labor of \$20.1 million.
- Rising rates of inflation and interest could result in increased costs that may not be offset by increases in Medicare, Medicaid, commercial and other payor rates.
- Market fluctuations and volatility could impact investment income of the Medical Center and its affiliates, and required pension plan funding.
- Expansion of telemedicine services and elimination of certificate of need requirements in the State of Florida may lead to greater competition and lower patient volumes and revenues.
- Respiratory Syncytial Virus Infection (RSV) and/or other viral infections, or new public health
 emergencies, could affect the Medical Center's ability to maintain clinical staffing levels and provide
 services.
- Severe weather, including hurricanes and tropical storms, could impact the ability of the Medical Center to provide services, and could result in increased costs and a negative local economic impact.
- The laws and regulations governing the Medicare and Medicaid program are complex and subject to change. As such, changes to these programs could have a negative effect on the financial performance of the Halifax Health. Audits of hospital compliance with Medicare and Medicaid program laws and regulations present exposure for repayments and fines and penalties.
- Federal and State initiatives:
 - The State of Florida has not approved Medicaid expansion, which has constrained state funding.
 - o Federal legislative efforts, both directly and via tax reform, could significantly reduce access to individual insurance coverage currently provided under Federal programs.
 - The State of Florida Low Income Pool ("LIP") Program has been extended to June 30, 2030.
 Payments from the LIP program have been limited to the cost of charity care services provided, meaning that LIP funds are not available to offset Medicaid costs in excess of Medicaid payments.

Management's Discussion and Analysis (Unaudited) Year Ended September 30, 2023

- Medicaid special payment programs that began during fiscal year 2021, Hospital Directed Payment Program and Physician Directed Payment Program, designed to offset (but not eliminate) Medicaid costs in excess of Medicaid payments, could result in DSH and LIP cost limits to be exceeded and amounts being paid back in the future.
- The Federal Affordable Care Act ("ACA") enacted in March 2010, includes reduction in Medicaid disproportionate share funding of \$4 billion in 2020 (which was delayed due to the COVID-19 pandemic) and \$8 billion each year from 2021 to 2025, which could reduce payments to Halifax Health unless the cuts are further delayed by Congress. In addition, the "Build Back Better Act," adopted by the House of Representatives in November 2021 with support of President Biden, includes provisions that could further reduce Medicaid disproportionate share funding.
- o The Statutory Pay-As-You-Go Act of 2010 will cause a 4% reduction in Medicare spending, including payments to hospitals, beginning in 2023, unless Congress waives these payment cuts.
- The Centers for Medicare & Medicaid Services (CMS) revised their regulations on the counting of Medicaid days in the disproportionate share hospital (DSH) calculation associated with certain section 1115 demonstrations. These changes are effective for patients discharged on or after October 1, 2023. As a result, providers will no longer be able to claim certain days associated with section 1115 waiver demonstrations. The rule will reduce Medicare DSH payments for hospitals and could impact a hospital's Medicare DSH and uncompensated care qualification or 340B program qualification. CMS estimates that excluding these days may result in a \$348 million annual reduction in the Medicare DSH payments to those impacted providers. CMS also acknowledges that the estimate is uncertain and the actual impact may be higher or lower.
- CARES Act Provider Relief Funds received are subject to audit and certain amounts could be at risk of being paid back in the future.
- Bundled payments and value-based payment initiatives of the Medicare program may reduce net payments received by Halifax Health.

The uncertainties listed above may adversely impact future operating results and financial position. The estimated effects of these matters have been considered in the development of the fiscal year 2023 Halifax Health operating budget.

Statement of Net Position September 30, 2023 (In Thousands)

Assets and Deferred Outflow

Current Assets:	
Cash and cash equivalents	\$ 172,860
Investments	337,733
Current assets whose use is limited—Trustee-held	,
self-insurance funds	229
Accounts receivable, patients, net of estimated	
uncollectibles of \$84,872	84,721
Inventories	20,700
Current portion of rent receivable	1,793
Other current assets	19,342
Total current assets	637,378
Noncurrent Assets Whose Use is Limited:	
Board-designated, funded depreciation	26,734
Restricted by donor	5,671
Board-designated, other	2,650
Investment in securities loan agreement	132,065
Depreciable capital assets, net	344,544
Nondepreciable capital assets	106,589
Right to use assets, net	27,810
Rent receivable	4,494
Other assets	 18,401
Total assets	1,306,336
Deferred Outflows:	
Interest rate swap	8,310
Pension, contribution after measurement	16,600
Pension, other	32,483
Deferred outflows related to other postemployment benefits	1,172
Loss on refunding of debt, net	 11,198
Total deferred outflows	 69,763
Total assets and deferred outflows	\$ 1,376,099

(Continued)

Statement of Net Position (Continued) September 30, 2023 (In Thousands)

Liabilities,	Deferred	Inflows	and Ne	t Position

Current Liabilities:	
Accounts payable and accrued liabilities	\$ 125,703
Accrued payroll and personal leave time	31,255
Current portion of accrued self-insurance liability	4,285
Current portion of long-term debt	9,635
Current portion of lease liabilities	2,170
Current portion of SBITA liabilities	5,532
Interest payable on long-term debt	5,752
Other current liabilities	 4,369
Total current liabilities	188,701
Noncurrent Liabilities:	
Long-term debt, less current portion	439,250
Long-term lease liabilities, less current portion	10,775
SBITA liabilities, less current portion	10,156
Premium on long-term debt, net	8,434
Net pension liability	60,302
Other postemployment benefits liability	16,731
Accrued self-insurance liability, less current portion	8,465
Other liabilities	9,017
Securities loan agreement obligation	132,065
Long-term value of interest rate swap	 8,310
Total liabilities	892,206
Deferred inflows related to leases	6,081
Deferred inflows related to other postemployment benefits	249
Total liabilities and deferred inflows	 898,536
Net Position:	
Net investment in capital assets	38,843
Restricted by donors, expendable	5,427
Restricted by donors, nonexpendable	244
Unrestricted	 433,049
Total net position	 477,563
Total liabilities, deferred inflows and net position	\$ 1,376,099

Statement of Revenues, Expenses and Changes in Net Position Year Ended September 30, 2023 (In Thousands)

Operating Revenues:	
Net patient service revenue,	
before provision for bad debts	\$ 793,919
Provision for bad debts	 (59,042)
Net patient service revenue	734,877
Ad valorem tax revenue	20,640
Other revenue	 30,940
Total operating revenues	786,457
Operating Expenses:	
Salaries and benefits	369,270
Supplies	149,290
Purchased services	150,529
Depreciation and amortization	34,678
Ad valorem tax-related expenses	6,794
Leases and rentals	5,014
Other	 31,949
Total operating expenses	 747,524
Income from operations	38,933
Nonoperating Revenues (Expenses):	
Interest expense	(21,497)
Investment income—SLA	1,931
Investment income—net	21,527
Donation revenue	759
Nonoperating gains—net	 2,698
Total nonoperating revenues (expenses), net	5,418
Excess of revenues over expenses	44,351
Contributions	 12,000
Increase in net position	56,351
Net Position:	
Beginning of year	 421,212
End of year	\$ 477,563

Statement of Cash Flows Year Ended September 30, 2023 (In Thousands)

Cash Flows from Operating Activities:	
Receipts from third-party payors and patients	\$ 722,846
Payments to employees	(375,863)
Payments to suppliers	(292,088)
Other receipts	53,143
Other payments	 (58,357)
Net provided by operating activities	49,681
Cash Flows from Noncapital Financing Activities:	
Proceeds from donations received	759
Other nonoperating gains	 2,698
Net cash provided by noncapital financing activities	 3,457
Cash Flows from Capital and Related Financing Activities:	
Acquisition of capital assets	(43,298)
Principal paid on long-term debt	(9,190)
Payment of interest on long-term debt	 (21,030)
Net cash used in capital and related financing activities	(73,518)
Cash Flows from Investing Activities:	
Realized investment income	13,487
Investment income—SLA	1,931
Purchase of investments and assets whose use is limited	(24,021)
Proceeds from sales and maturities of investments and	
assets whose use is limited	 6,978
Net cash used in investing activities	 (1,625)
Net decrease in cash and cash equivalents	(22,005)
Cash and Cash Equivalents:	
Beginning of year	 194,865
End of year	\$ 172,860

(Continued)

Statement of Cash Flows (Continued) Year Ended September 30, 2023 (In Thousands)

Reconciliation of Income from Operations to Net Cash	
Provided by Operating Activities:	
Income from operations	\$ 38,933
Adjustments to reconcile income from operations to net cash	
provided by operating activities:	
Depreciation and amortization expense	34,678
Change in unrealized gains and losses on investments considered operating activity	(3,700)
Provision for bad debts	59,042
Changes in assets and liabilities:	
Accounts receivable, patients	(71,073)
Inventories and other current assets	1,278
Rent receivable	1,911
Other assets	(5,416)
Deferred outflows, pension contribution after measurement date	4,715
Deferred outflows, pension other	(32,483)
Deferred outflows related to other postemployment benefits	98
Deferred outflows, loss on refunding of debt	859
Accounts payable and accrued liabilities	18,903
Lease and SBITA payments	(6,920)
Other liabilities	25,973
Deferred inflows related to pension	(15,073)
Deferred inflows related to leases	(1,996)
Deferred inflows related to other postemployment benefits	(48)
Net cash provided by operating activities	\$ 49,681
Noncash operating activities:	
Lease and SBITA liabilities incurred in connection with right to use assets	\$ 21,069
	_
Noncash investing activities:	
Change in unrealized gains and losses on investments and assets whose use is limited	\$ 7,678
Noncash capital and related financing activities:	
Reclassification of prior year contributions from liability to net position	\$ 12,000
Securities lending agreement	\$ (1,925)
Change in fair value of interest rate swap	\$ 5,417
- J	 <u> </u>
Noncash investing and financing activities:	
Acquisition of capital assets included in accounts payable and accrued liabilities	\$ 19,601
	 - ,

Statement of Fiduciary Net Position September 30, 2023 (In Thousands)

Assets:	
Investments, at fair value:	
Money market funds	\$ 989
Mutual funds	185,229
Pooled, common and collective funds	128,941
Accrued income	 2
Total investments	 315,161
Contribution receivable	476
Net assets restricted for pension benefits	\$ 315,637
Liabilities and Net Position:	
Accounts payable	\$ 7
Net position	315,630
Total liabilities and net position restricted for pension benefits	\$ 315,637

Statement of Changes in Fiduciary Net Position Year Ended September 30, 2023 (In Thousands)

Additions:	
Investment results:	
Appreciation in fair value of investments	\$ 30,908
Interest and dividends	 3,662
Net investment income	34,570
Employer contributions	16,678
Total investment income and employer contributions, net	 51,248
Deductions:	
Administrative expenses	43
Benefits paid directly to participants	21,675
Total deductions	21,718
Increase in net position restricted for pension benefits	29,530
Net Position Restricted for Pension Benefits:	
Beginning of year	286,100
End of year	\$ 315,630

Notes to Financial Statements

Note 1. Description of the Organization

Reporting Entity: Halifax Hospital Medical Center (the "Medical Center") d/b/a Halifax Health was created by a special act of the Legislature of the State of Florida, Chapter 2003-374, Laws of Florida, as a special taxing district (the "District"), a public body corporate and politic of the State of Florida and successor to Halifax Hospital District created pursuant to Chapter 112.72, Laws of Florida, Special Acts of 1925. The Medical Center's Board of Commissioners (the "Board") is empowered to levy ad valorem taxes for operating expenses, capital outlays, and other purposes.

The Medical Center, located in Daytona Beach, Florida, is a full-service, accredited, acute care hospital licensed to operate 673 beds. The Medical Center owns and operates three inpatient hospital facilities under one license and several ambulatory facilities. The main campus of the Medical Center is the inpatient referral center, providing Level III neonatal intensive care and a Level II state-certified trauma center, in addition to open-heart surgery, neurosurgery, and other specialty inpatient and outpatient services. The Port Orange campus, located 10 miles south of the main campus, is a community hospital providing a broad range of services to the residents of Port Orange and Southeast Volusia County. The Halifax Behavioral Services campus, located two miles north of the main campus, provides child, adolescent, and adult inpatient and outpatient psychiatric services to the residents of Volusia and Flagler Counties.

As required by accounting principles generally accepted in the United States of America ("GAAP"), these financial statements represent the primary government, the Medical Center, and its component units. The component units discussed below are included because of the significance of their operational or financial relationships with the Medical Center. The Medical Center, together with its component units, is referred to as "Halifax Health." All significant intercompany accounts and balances have been eliminated in the financial statements.

Component Units: East Volusia Health Services, Inc. ("EVHS"); Halifax Healthcare Systems, Inc. ("HHCSI"), HH Holdings, Inc. ("Holdings"); Halifax Healthy Families Corporation d/b/a Healthy Communities ("Healthy Communities"); Halifax Staffing, Inc. ("Staffing"); Patient Business & Financial Services, Inc. ("PBFS"); Halifax Hospice, Inc. d/b/a Halifax Health Hospice ("Hospice"); Halifax Management System, Inc. ("HMS"); Halifax Medical Center Foundation, Inc. ("Foundation"); Medical Center of Deltona, Inc. ("MCD") and Volusia Health Ventures, Inc. d/b/a Volusia Health Network ("VHN") are legally separate organizations which represent component units of the Medical Center.

Each component unit was established to provide administrative and other services for and on behalf of the Medical Center. In accordance with Governmental Accounting Standards Board Statement No. 80, these entities are blended within the financial results of the Medical Center because they are organized as not-for-profit corporations and the Medical Center is the sole corporate member of each component unit, with the exception of HMS and VHN. HMS is blended within the financial results of the Medical Center in accordance with Governmental Accounting Standards Board Statement No. 61 because it has a specific financial benefit to the Medical Center, and management of the Medical Center have operational responsibility for the results of HMS. The activities of VHN are not considered material to the Medical Center.

EVHS is a not-for-profit corporation organized under the laws of Florida. EVHS was organized for the purpose of entering into joint-venture agreements to enhance the access and quality of patient care provided to the community.

HHCSI is a not-for-profit corporation organized under the laws of Florida. HHCSI was organized for the purpose of enhancing the access and quality of patient care provided to the community.

Notes to Financial Statements

Note 1. Description of the Organization (Continued)

Holdings is a not-for-profit corporation organized under the laws of Florida that was established to manage the remaining assets that resulted from the sale of Florida Health Care Plan in 2008.

Healthy Communities is a not-for-profit corporation organized under the laws of Florida that coordinates the delivery of education, health resources, and direct assistance to the community. The services provided by Healthy Communities include administering Healthy Kids (child health insurance program), facilitating the provision of preventive care, and providing education and other activities relating to the general welfare of all children in Volusia and Flagler counties.

Staffing is a not-for-profit corporation organized under the laws of Florida, formed for the purpose of providing individuals to staff and manage the Medical Center, its component units, and other related entities and facilities. The Medical Center is obligated to reimburse Staffing for all costs incurred in meeting its obligations under an agreement between the parties.

PBFS is a not-for-profit corporation that operates the patient accounting services for the Medical Center and employs certain staff for this function.

MCD is a not-for-profit corporation, incorporated in the state of Florida, operating an accredited, 43-bed acute care hospital located in the City of Deltona, Florida.

Hospice was organized in 1984 as a not-for-profit corporation under the laws of Florida. Hospice provides palliative medical care and treatment to patients who have less than six months to live via four inpatient care centers and in-home hospice services. The Port Orange care center is a 16-bed inpatient care center located in Port Orange. The West Volusia care center is an 18-bed center in Orange City. The Southeast Volusia care center is a 12-bed facility located in Edgewater. The Ormond Beach Care Center is a 12-bed facility.

HMS was organized in 1984 as a not-for-profit corporation under the laws of Florida. HMS owns and leases to the Medical Center three ambulatory facilities and one hospital facility and to MCD one medical office building. Facilities located in Ormond Beach, Deltona and on the Medical Center's main campus in Daytona Beach provide outpatient hospital services and medical offices. The third facility located in Port Orange is an 80-bed inpatient hospital.

The Foundation was organized in 1988 as a not-for-profit corporation under the laws of Florida. The Foundation is the fund-raising organization for the Medical Center.

VHN was organized in 1984 as a not-for-profit corporation under Florida law. VHN operates a preferred provider network of physicians and hospitals in the service area and offers the network and certain related services to employers that are self-insured for the health insurance coverage of their employees.

EVHS has a 95% interest in Daytona Area Senior Services ("DASS") d/b/a Halifax Health Care at Home, which provides home health services to the residents of the local area. DASS' financial activity is included in these financial statements.

Notes to Financial Statements

Note 1. Description of the Organization (Continued)

Presented on the following pages are condensed combining schedules for the component units.

Condensed Combining Statement of Net Position September 30, 2023 (In Thousands)

	Me	edical							В	lended Con	npon	ent Units							Inte	ercompany	Halifax
	Ce	enter	-	Holdings	5	Staffing	PBFS	HHCSI		EVHS		Hospice	١	/HN	Fo	oundation	MCD	HMS	EI	iminations	Health
Assets and Deferred Outflows				<u> </u>								·									
Current assets	\$ 2	238,691	\$	181,323	\$	_	\$ -	\$ 351	\$	18,453	\$	115,753	\$	3	\$	54,969	\$ 26,039	\$ 19,932	\$	(18,137)	\$ 637,377
Noncurrent assets whose use is limited		26,734		-		-	-	-		-		2,650		-		5,671	-	-		-	35,055
Capital and right to use assets, net	3	323,827		18,966		-	-	1,375		336		17,778		-		-	117,257	20,552		(21,148)	478,943
Other assets and deferred outflows		76,050		1,350		-	-	_		11,997		6,665		-		-	133,296	17,140		(21,774)	224,724
Total assets and deferred outflows	\$ 6	65,302	\$	201,639	\$	-	\$ -	\$ 1,726	\$	30,786	\$	142,846	\$	3	\$	60,640	\$ 276,592	\$ 57,624	\$	(61,059)	\$ 1,376,099
Liabilities, Deferred Inflows and Net Position																					
Current liabilities	\$ 1	172,986	\$	157	\$	-	\$ -	\$ 1,291	\$	-	\$	4,047	\$	392	\$	-	\$ 26,212	\$ 1,753	\$	(18,137)	\$ 188,701
Long-term debt, less current portion	3	309,210		-		-	-	_		-		-		-		-	130,040	-			439,250
Other liabilities and deferred inflows	1	139,480		401		-	-	1,247		229		6,547		-		1,852	135,776	27,975		(42,922)	270,585
Total liabilities and deferred inflows	6	621,676		558		-	-	2,538		229		10,594		392		1,852	292,028	29,728		(61,059)	898,536
Net Position:																					
Net investment in capital assets		9,868		18,854		-	-	(46)		(2)		15,588		-		-	(18,072)	11,882		771	38,843
Restricted by donors, expendable		-		-		-	-	-		-		-		-		5,427	-	-		-	5,427
Restricted by donors, nonexpendable		-		-		-	-	-		-		-		-		244	-	-		-	244
Unrestricted (deficit)		33,758		182,227				(766)		30,559		116,664		(389)		53,117	2,636	16,014		(771)	433,049
Total net position		43,626		201,081		-	-	(812)		30,557		132,252		(389)		58,788	(15,436)	27,896		-	477,563
Total liabilities, deferred inflows and net position	\$ 6	665,302	\$	201,639	\$	_	\$ _	\$ 1,726	\$	30,786	\$	142,846	\$	3	\$	60,640	\$ 276,592	\$ 57,624	\$	(61,059)	\$ 1,376,099

Notes to Financial Statements

Note 1. Description of the Organization (Continued)

Condensed Combining Statement of Revenues, Expenses and Changes in Net Position Year Ended September 30, 2023 (In Thousands)

	Medical				E	Blended Com	nponent Units					Inte	rcompany	H	Halifax
	Center	Holdings	Staffing	PBFS	HHCSI	EVHS	Hospice	VHN	Foundation	MCD	HMS	Elir	minations	H	lealth
Operating revenues	\$ 658,783	\$ 1,807	\$ -	\$ -	\$ 2,658	\$ 8,705	\$ 57,619	\$ 1,130	\$ 7,773	\$ 47,164	\$ 5,152	\$	(4,334)	\$	786,457
Operating expenses, before depreciation and															
amortization	275,980	363	295,530	30,410	3,263	4,036	51,325	1,000	899	49,387	1,007		(354)		712,846
Depreciation and amortization	28,000	556	-	-	246	27	1,124	-	-	6,783	1,922		(3,980)		34,678
Total operating expenses	303,980	919	295,530	30,410	3,509	4,063	52,449	1,000	899	56,170	2,929		(4,334)		747,524
Income (loss) from operations	354,803	888	(295,530)	(30,410)	(851)	4,642	5,170	130	6,874	(9,006)	2,223		-		38,933
Nonoperating revenues (expenses)	(331,999)	5,025	295,530	30,410	-	-	11,081	-	-	(5,134)	505		-		5,418
Contributions		-	-	-	-	-	-	-	-	12,000	-		-		12,000
Increase (decrease) in net position	\$ 22,804	\$ 5,913	\$ -	\$ -	\$ (851)	\$ 4,642	\$ 16,251	\$ 130	\$ 6,874	\$ (2,140)	\$ 2,728	\$	_	\$	56,351

Notes to Financial Statements

Note 1. Description of the Organization (Continued)

Condensed Combining Statement of Cash Flows Year Ended September 30, 2023 (In Thousands)

		Medical						E	Blenc	ded Compor	nent	Units						Inte	ercompany	Halifax
Net cash provided by (used in):		Center	Holding	3	Staffing	PBFS	H	HCSI		EVHS	I	Hospice	VHN	Fo	undation	MCD	HMS	Eli	minations	Health
Operating Activities Noncapital Financing Activities	\$	354,372 (322,309)	\$ (1,893 767	,	(295,530) 295,530	\$ (30,410) 30,410	\$	-	\$	1,397 (1,339)	\$	5,050 398	\$ -	\$	3,061	\$ 11,090 -	\$ 2,719	\$	-	\$ 49,856 3,457
Capital and Related Financing Activities		(55,610)	(7,402	,	-	-		-		(463)		(506)	-		- (4.200)	(9,668)	(44)		-	(73,693)
Investing Activities Net increase (decrease) in cash	_	14,638	(5,429)	-	-				(1,497)		(6,823)			(4,366)	1,478	374		-	(1,625)
and cash equivalents		(8,909)	(13,957)	-	-		-		(1,902)		(1,881)	-		(1,305)	2,900	3,049		-	(22,005)
Cash and Cash Equivalents:																				
Beginning of year		120,157	19,604		-	-		-		17,704		10,322	-		2,731	11,654	12,693		-	194,865
End of year	\$	111,248	\$ 5,647	\$	-	\$ -	\$	-	\$	15,802	\$	8,441	\$ -	\$	1,426	\$ 14,554	\$ 15,742	\$	-	\$ 172,860

Notes to Financial Statements

Note 1. Description of the Organization (Continued)

<u>Fiduciary Fund Financial Statements</u>: The Pension Trust Fund (the "Pension Fund"), the fiduciary fund, is used to account for the net position restricted for the pension benefits of certain employees of Staffing and Hospice.

Note 2. Significant Accounting Policies

A summary of the significant accounting policies used by Halifax Health follows:

<u>Accounting Standards</u>: These financial statements have been prepared in accordance with the Governmental Accounting Standards Board ("GASB") codification ("GASB Cod."). The financial statements of the component units are also prepared in accordance with the GASB codification, as they are established for the direct benefit of the Medical Center. The financial statements of the Medical Center and its component units have been prepared on the accrual basis of accounting.

<u>Cash and Cash Equivalents</u>: All unrestricted highly liquid investments with maturities of three months or less when purchased are considered cash equivalents, excluding cash and cash equivalents included in assets whose use is limited. Cash deposits are fully collateralized and federally insured up to Federal Deposit Insurance Corporation limits.

<u>Investments</u>: Investments are reported at fair value or amortized cost, if not materially different from fair value. Investments are marketable securities representing the investment of cash available for current operations, and as such are reported as current assets. Interest and dividends, when earned, and realized and changes in unrealized investment gains and losses are recorded as nonoperating revenue and expenses in the statement of revenues, expenses, and changes in net position, with the exception of the Foundation. Interest and dividends, when earned, and realized and changes in unrealized investment gains and losses of the Foundation are recorded as operating revenue in the accompanying statement of revenues, expenses and changes in net position.

<u>Master Securities Loan Agreement</u>: Halifax Health lends securities to other entities (borrowers) for collateral that will be returned for the same securities in the future under Master Securities Loan Agreements ("MSLA"). MCD entered into an MSLA with JP Morgan Chase Bank, N.A. ("JPMC"). The securities are recorded as a noncurrent asset and a noncurrent liability in the statement of net position.

Assets Whose Use is Limited: Assets whose use is limited are marketable securities that are designated and set aside and controlled by the Board for repair and replacement of capital assets and for other purposes. The Board retains control of, and may use, these designated assets for purposes other than those for which the assets were initially designated.

<u>Capital Assets</u>: Purchases of real property and equipment of \$5,000 or greater that have a useful life of longer than one year are capitalized at cost. The costs of replacement assets are capitalized in the same manner. The cost of minor equipment less than \$5,000 and repairs are recorded in operating expenses.

Capital assets are reviewed and considered for impairment whenever indicators of impairment are present, such as the decline in service utility of a capital asset that is large in magnitude and the event or change in circumstance is outside the normal life cycle of the capital asset.

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

<u>Depreciation and Amortization</u>: Capital assets, excluding land and construction in progress, are depreciated on a straight-line basis over the estimated useful lives of the related assets. Estimated useful lives range from 5 to 20 years for building improvements, 10 to 40 years for buildings, 10 to 20 years for fixed equipment, and 3 to 20 years for major movable equipment. Capitalized intangible assets and goodwill are amortized over their estimated useful lives of three years and five years, respectively. Bond premium (discount) is reported in the accompanying financial statements as an increase (deduction) from long-term debt and is deferred and amortized in a manner that approximates the effective interest method.

<u>Leases</u>: A lease asset is determined at inception when the control of the right to use underlying asset belongs to the entity for the term of the lease for a period of one year or greater. The term of the lease may include exercisable options when reasonably certain the option will be renewed. Right to use assets are amortized in a systematic and rational manner over the shorter of the lease terms or useful life of the underlying asset.

Leases, in which Halifax Health is the lessee, are included as right to use assets, net of amortization, in accordance with GASB Statement No. 87, *Leases* ("GASB 87"), in the statement of net position at the present value of expected lease payments over the lease term, adjusted for lease incentives, if applicable. Lease liabilities and rent receivables are based initially at the present value of lease payments or receipts, respectively, over the course of the lease and is re-measured whenever there is a change or modification of the lease terms. The current and long-term lease liabilities are recorded in the statement of net position.

Payments for leases, in which Halifax Health is the lessor, are recorded as a rent receivable and a deferred inflows related to leases. Terms vary by lease, each providing a monthly lease payment subject to a fixed escalation on the anniversary date of the agreement. As lease payments are received, deferred inflows are accreted as rental revenue and the interest income is included in investment income in the statement of revenue, expenses and change in net position.

For leases recorded, the rates are based upon the incremental borrowing rate and vary based on inception date and terms of the contract. Current rates range from 0.59% to 6.20%.

<u>Subscription-Based Information Technology Arrangements</u>: Subscription-Based Information Technology Arrangements ("SBITA") is defined as a contract that conveys control of the right to use another party's information technology software, alone or in combination with tangible capital assets, as specified in the contract for a period of time in an exchange or exchange-like transaction. A SBITA is included as right to use asset and corresponding SBITA liability in accordance with GASB Statement No. 96, *Subscription-Based Information Technology Arrangements* ("GASB 96").

For SBITAs recorded, the rates are based upon the incremental borrowing rate and vary based on inception date and terms of the contract. Current rates range from 5.0% to 5.7%.

<u>Intangible Assets</u>: Certain intangible assets, other than right to use assets, are capitalized in accordance with GASB Cod. Sec. 1400, *Reporting Capital Assets*. Generally, those intangible assets would meet the same criteria for capitalization as other capital assets, cost of \$5,000 or greater and a useful life of longer than one year.

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

<u>Debt Issuance Costs and Unamortized Bond Premium (Discount)</u>: Debt issuance costs are expensed as incurred. Unamortized bond premiums and discounts are amortized over the period the related obligation is outstanding. The amortization of bond premiums and discounts are included as a component of interest expense.

<u>Derivative Instruments</u>: The Medical Center has entered into an interest rate-swap agreement (the "Swap") and applies hedge accounting in accordance with GASB Cod. Sec. D40, *Derivative Instruments*. For effective hedging instruments, the change in fair value is recorded as a deferred outflow on the accompanying statement of net position, and the fair value of the Swap is reported in noncurrent liabilities. See Note 9 for more information on the Swap.

<u>Deferred Outflows and Inflows</u>: In addition to the Swap described above, certain pension costs, other postemployment benefits, leases, and losses on refunding of debt in prior years are included in deferred outflows and inflows and amortized over a specified period. Amortization of pension and other postemployment benefits related deferred outflows and inflows is included in salaries and benefits expense in the accompanying statement of revenues, expenses and changes in net position. Amortization of leases related to deferred inflows are included in other operating revenue in the accompanying statement of revenues, expenses and changes in net position.

<u>Inventories</u>: Inventories consist of medical supplies, which are stated at the lower of cost or market (on a first-in, first-out basis).

<u>Personal Leave Time</u>: Personal leave time, which includes holiday, sick, and vacation time, that is accrued but not used at September 30, 2023, is included in accrued payroll and personal leave time in the accompanying statement of net position.

<u>Pension Plan</u>: The Halifax Pension Plan (the "Plan") is a cost-sharing, multiple-employer, noncontributory defined benefit pension plan that covers certain employees of the two participating employers, Hospice and Staffing. The Plan is accounted for in accordance with GASB Cod. Sec. Pe5, *Pension Plans—Defined Benefit*. Contributions are made based on the minimum recommended contribution as determined by actuarial valuation. The Plan is considered a governmental plan exempt from Employee Retirement Income Security Act requirements based upon rulings received from the Internal Revenue Service. See Note 10 for more information on the Plan.

<u>Self-Insurance</u>: Halifax Health is self-insured for various risks of loss, including professional and general liability losses, workers' compensation claims, and employees' health claims. Estimated liabilities include known claims and claims that have been incurred but not reported. The noncurrent portion of estimated professional and general liability losses and workers' compensation claims have been discounted using a 4% and 2%, respectively, interest rate for 2023. Estimated losses for employees' health claims are not discounted as all amounts are considered current liabilities. See Note 6 for more information on self-insurance liabilities.

<u>Income Taxes</u>: The Medical Center is tax exempt under Section 115 of the Internal Revenue Code ("IRC"). With the exception of VHN, all of the component units are not-for-profit corporations described in Section 501(c)(3) of the IRC and are exempt from federal and state income taxes on related income pursuant to Section 501(a) of the IRC and Chapter 220.13 of the Florida Statutes, respectively. VHN is a taxable Florida not-for-profit corporation. There was no material amount of tax expense or benefit for the year ended September 30, 2023.

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

<u>Net Position</u>: In accordance with GASB Cod. Sec. 2200, *Comprehensive Annual Financial Report*, net position is reported in three components: net investment in capital assets, restricted, and unrestricted. Net investment in capital assets consists of right to use assets net of accumulated amortization, capital assets net of accumulated depreciation and reduced by the outstanding balances of any debt issued that is attributable to the acquisition, construction, or improvement of those capital assets. If there are significant unspent related debt proceeds at year-end, the portion of the debt attributable to the unspent proceeds are not included in the calculation of net investment in capital assets.

The restricted component of net position consists of restricted assets; assets that have constraints placed on them externally by creditors, grantors, contributors, or laws or regulations of other governments, or laws through constitutional provisions or enabling legislation, reduced by liabilities or deferred inflows related to those restricted assets.

The unrestricted component of net position consists of the net amount of assets, deferred outflows of resources and liabilities, and deferred inflows of resources that do not meet the definitions of the other two components of net position.

<u>Use of Estimates</u>: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Revenue and Expenses: For purposes of presentation, transactions deemed by management to be ongoing, major, or central to the provision of health care services are reported as operating revenue and expenses. Peripheral or incidental transactions, such as interest expense, donations, and investment income (loss) are reported as nonoperating revenues, expenses, gains, and losses, with the exception of the Foundation. Investment income (loss) of the Foundation is recorded as operating revenue in the accompanying statement of revenues, expenses and changes in net position.

Ad valorem taxes levied and received by the Medical Center are designated by law to fund the Medical Center's operating expenses, which may include maintenance, construction, improvements, and repairs to the Medical Center or fund other expenses in carrying out the business of the Medical Center. The Medical Center considers ad valorem tax receipts to be ongoing and central to the provision of health care services and, accordingly, classifies these funds as operating revenue.

Ad valorem taxes received by the Medical Center are based on the assessed valuation of certain taxable real and personal property at the Board-approved millage rate for the year. Gross receipts of \$20.6 million are included in operating revenues in the accompanying statement of revenues, expenses, and changes in net position. Certain expenses directly attributable to the Medical Center's status as a taxing authority are classified as ad valorem tax-related expenses. These expenses, when added to the charity care and other uncompensated care provided to qualifying patients, exceed ad valorem taxes received and are considered by the Board when determining the tax levy.

Substantially all expenses, including those expenses directly attributable to the Medical Center's status as a taxing authority, are considered by management to be ongoing and central to the provision of health care services and, therefore, are reported as operating expenses.

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

When an expense is incurred for which both unrestricted and restricted resources are available, restricted resources are applied first.

Net Patient Accounts Receivable: Net patient accounts receivable are reported at estimated net realizable amounts due from patients, third-party payors, and others for services rendered. The provision for bad debts is based on management's assessment of historical and expected net collections, considering business and economic conditions, trends in health care coverage, and other collection indicators. Throughout the year, management assesses the adequacy of the allowance for uncollectible accounts based upon these trends. The results of this review are then used to make any modifications to the provision for bad debts and to establish an appropriate estimated allowance for uncollectible accounts. Specific patient accounts identified as uncollectible are written off to the allowance for uncollectible accounts.

<u>Net Patient Service Revenue</u>: The Medical Center, MCD, Hospice and DASS serve certain patients whose medical costs are not paid at established rates. These include patients sponsored under government programs, such as Medicare and Medicaid, patients sponsored under private contractual agreements, and uninsured patients who have limited ability to pay.

Net patient service revenue is reported at estimated net realizable amounts due from patients, third-party payors, and others when services are rendered, and includes estimated retroactive revenue adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations. Approximately \$29.3 million in amounts due to Medicare and Medicaid relating to estimated future retroactive adjustments is recorded in accounts payable and accrued liabilities.

Revenue from the Medicare and Medicaid programs accounted for approximately 55% of net patient service revenue for the year ended September 30, 2023. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Adjustments to revenue are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as changes in estimated provisions and final settlements are determined. There were no significant adjustments to revenue related to prior periods during the year ended September 30, 2023.

The Medical Center, MCD and Hospice classify a patient as charity based on established policies. These policies define charity services as those services for which no additional payment is anticipated. When assessing a patient's ability to pay, the Medical Center and MCD utilize percentages of the federal poverty income levels, as well as the relationship between charges and the patient's income. Beginning fiscal year 2016, the Medical Center's policy was revised from 200% to 400% of the federal poverty income level and has been applied to current MCD practices. Hospice classifies charity patients as those whose income is at or below the federal poverty guidelines. Core services may be covered in full, or discounted based on income and a sliding scale. Charity care, based on estimated costs, totaled approximately \$42.8 million for the year ended September 30, 2023. Cost of charity care is calculated by applying the cost-to-charge ratio to the total amount of charity care deductions from gross revenue. The cost-to-charge ratio is calculated by taking the total expenses, excluding bad debt, and dividing by gross charges of the Medical Center and MCD.

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

Net patient service revenue is reported net of charity adjustments, contractual adjustments, and provision for bad debts for the year ended September 30, 2023, as follows (in thousands):

Gross patient charges	\$	3,112,721
Charity adjustments		(178,411)
Contractual adjustments	(2,140,391)
Net patient service revenue before		
provision for bad debts		793,919
Provision for bad debts		(59,042)
Net patient service revenue	\$	734,877

Other Funding Sources: Halifax Health receives funding from various components of the State Medicaid program. Funding sources include Low Income Pool ("LIP"), Disproportionate Share Hospital ("DSH"), Indirect Medical Education ("IME"), Graduate Medical Education ("GME"), Hospital Directed Payment Program ("DPP"), and Public Hospital Payment ("PHP").

The LIP program distributes funding to Halifax Health in support of programs that provide coverage for uninsured and underinsured patients. The LIP is a federal matching program that provides the State with the opportunity to receive additional distributions based upon a fixed annual pool of approximately \$1.5 billion distributed based on a measure of charity care cost.

The DSH program distributes funding to Halifax Health as add-on payments for hospitals that treat a disproportionate number of low-income patients. These payments help hospitals continue to serve impoverished communities.

IME requires a hospital to have approved GME programs. These programs provide additional payments for a Medicare discharge to reflect the higher patient care costs of teaching hospitals relative to non-teaching hospitals.

DPP is administered regionally and is to help reduce the Medicaid shortfall experienced by hospitals. The program provides direct supplemental payments to eligible public and private entities that provide inpatient and outpatient services to Medicaid managed care recipients.

PHP provides supplemental payments for services provided by Doctor of Medicine or Osteopathy, as well as other licensed health care practitioners, to support access to high quality care in a public hospital in Florida.

The programs above are subject to governmental administrative approval and provider-specific cost limits which are retrospectively audited. The Medical Center recognized revenue related to these other funding sources within net patient service revenue. The following table shows the amounts by program for the year ended September 30, 2023:

LIP/DSH	\$ 20,128
IME	2,661
DPP	14,003
PHP	 2,011
Total other Medicaid payments	\$ 38,803

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

New Accounting Pronouncements: On October 1, 2022, Halifax Health adopted GASB Statement No. 96, Subscription-Based Information Technology Arrangements. This Statement provides guidance on the accounting and financial reporting for SBITAs for government end users. This statement establishes that a SBITA results in a right to use asset and a corresponding SBITA liability. The standard required Halifax Health to initially record right to use assets and SBITA liabilities totaling \$18.2 million in the statement of net position.

In May 2019, GASB issued Statement No. 91, *Conduit Debt Obligations*. This Statement requires that issuers disclose general information about their conduit debt obligations, organized by type of commitment, including the aggregate outstanding principal amount of the issuers' conduit debt obligations and a description of each type of commitment. Recognized liabilities related to supporting the debt service of conduit debt obligations should be disclosed by recognized amount and changes during the reporting period. The standard become effective and was adopted by Halifax Health for the fiscal year beginning October 1, 2022. This standard had no impact on the financial statements.

In March 2020, GASB issued Statement No. 93, *Replacement of Interbank Offered Rates*. This Statement addresses accounting and financial reporting implications that result from the replacement of an interbank offered rate. The standard became effective and was adopted by Halifax Health for the fiscal year beginning October 1, 2022.

Pending Accounting Pronouncements: In May 2022, GASB issued Statement No. 99, *Omnibus 2022*. The Statement provides guidance addressing various accounting and financial reporting issues identified during the implementation and application of certain GASB pronouncements, including: accounting and financial reporting for exchange or exchange-like financial guarantees; certain derivative instruments that are neither hedging derivative instruments nor investment derivative instruments; and clarification of certain provisions of: GASB Statement No. 34, *Basic Financial Statements—and Management's Discussion and Analysis—for State and Local Governments,* GASB Statement No. 87, *Leases,* as amended, GASB Statement 94, *Public-Private and Public-Public Partnerships and Availability Payment Arrangements,* and GASB Statement No. 96, *Subscription-Based Information Technology Arrangements.*

The requirements of this Statement are effective as follows:

- For GASB Statement No. 34, as amended, and terminology updates related to GASB Statement No. 53 and Statement No. 63, they are effective upon issuance.
- For GASB Statement No. 87, GASB Statement No. 94 and GASB Statement No. 96, they are effective for fiscal years beginning after June 15, 2022, and all reporting periods thereafter.
- For GASB Statement No. 53, they are effective for fiscal years beginning after June 15, 2023.

Halifax Health is evaluating the impact of this Statement on its financial statements.

In June 2022, GASB issued Statement No. 100, *Accounting Changes and Error Corrections*. The primary objective of GASB No. 100 is to enhance the accounting and financial reporting requirements for accounting changes and error corrections to provide more understandable, reliable, relevant, consistent, and comparable information for making decisions or assessing accountability. This standard is effective for fiscal years beginning after June 15, 2023. Halifax Health is evaluating the impact of this Statement on its financial statements.

Notes to Financial Statements

Note 2. Significant Accounting Policies (Continued)

In June 2022, GASB issued Statement No. 101, *Compensated Absences*. This Statement establishes accounting and reporting requirements for liabilities arising from certain types of compensated absence arrangements. This standard is effective for fiscal years beginning after December 15, 2023. Halifax Health is evaluating the impact of this Statement on its financial statements.

Note 3. Investments and Assets Whose Use is Limited

Halifax Health measures and records its investments and assets whose use is limited using fair value measurement guidelines established by GASB Statement No. 72. These guidelines recognize a three-tiered fair value hierarchy, as follows:

- Level 1: Quoted prices for identical investments in active markets;
- Level 2: Observable inputs other than quoted market prices; and
- Level 3: Unobservable inputs.

Debt and equity securities classified in Level 1 are valued using prices quoted in active markets for those securities. Securities classified in Level 2 are valued using the following approaches:

- U.S. Agencies and Commercial Paper: quoted prices for identical securities in markets that are not active; and
- Corporate and Municipal Bonds: quoted prices for similar securities in active markets.

Halifax Health measures and records its pooled investments using the net asset value ("NAV") per share or its equivalent guidelines established by GASB Statement No. 72.

A Pooled Investment Fund is a fund that combines money from many individual investors and invests in securities and other assets. They are not registered with the Securities and Exchange Commission as an investment company. Halifax can redeem up to 100% of its investment in any Pooled Investment Fund monthly with five-business days notice. As of September 30, 2023, Halifax Health has no unfunded commitments.

Parametric Portfolio Associates LLC ("Parametric") is managed through a management agreement. Participants share in the investment income, expenses, gains and losses of each Pooled Investment Fund based on their proportionate share as determined by units. The fair value of the position in the pool is the same as the value of the pool shares.

The Clarion Lion Properties Fund's ("Clarion") investment philosophy seeks to take advantage of changing conditions within the U.S. property and capital markets by periodically shifting allocations among property types and locations, while remaining focused on the management of a core equity real estate portfolio.

Lord Abbett Short Duration Income actively invests its portfolio in short-term investment grade bonds.

Lord Abbett Core Fixed Income actively invests its portfolio in investment grade bonds.

Notes to Financial Statements

Note 3. Investments and Assets Whose Use is Limited (Continued)

The composition and fair value classification of investments and assets whose use is limited of Halifax Health at September 30, 2023, is set forth in the following table:

Direct Investments (Fair Value)

						Assets V	Vhose	Use is Lim	ited	and Restrict	ted As	ssets	
				Γrustee-		Trustee-		Board-					
			Н	eld Self-		Held Funds		signated				Board	
				surance		for Capital		Funded		Restricted	D	esignated	
	Inve	estments		Funds		Projects		preciation		by Donor		Other	Total
							(In T	Thousands)					
Level 1	_		_		_		_		_		_		
Money market funds	\$	2,333	\$	229	\$	-	\$	106	\$	-	\$	-	\$ 2,668
Mutual funds:													
Chartwell Short Duration High Yield		7,596		-		-		-		-		-	7,596
DFA Emerging Markets Core Equity Portfolio		6,059		-		-		-		399		95	6,553
DFA International Large Cap Portfolio		12,945		-		-		-		887		279	14,111
DFA Small Cap Value Portfolio		3,337		-		-		-		1,856		430	5,623
DFA U.S. Large Cap Value Portfolio		3,241		-		-		-		2,284		868	6,393
Vanguard Global Min Vol Admiral Fund		15,686		-		-		-		-		-	15,686
Vanguard Growth Index Fund		4,947		-		-		-		-		60	5,007
Vanguard Total Stock Market Index Fund		30,497		-		-		-		-		-	30,497
Vanguard Short-Term Investment Grade Inst Fund		30,953		-		-		-		-		918	31,871
Vanguard Small Cap Growth Index Fund		2,962		-		-		-		-		-	2,962
U.S. Treasury obligations		69,440		-		-		17,129		-		-	86,569
Total Level 1		189,996		229		-		17,235		5,426		2,650	215,536
Level 2													
U.S. Government-sponsored enterprises:													
Federal National Mortgage Association		5,252		-		-		3,742		-		-	8,994
Federal Home Loan Bank		12,401		-		-		4,207		-		-	16,608
Federal Home Loan Mortgage Corporation		2,279		-		-		1,411		-		-	3,690
Corporate bonds		61,543		-		-		-		-		-	61,543
Other		1,853		-		-		139		245		-	 2,237
Total Level 2		83,328		-		-		9,499		245		-	93,072
Total Direct Investments	\$	273,324	\$	229	\$	-	\$	26,734	\$	5,671	\$	2,650	\$ 308,608

Notes to Financial Statements

Note 3. Investments and Assets Whose Use is Limited (Continued)

Pooled Investments (Net Asset Value)

					Assets V	Vhose	e Use is Lim	iited	and Restric	ted A	ssets	
	In	vestments	Trustee- Held Self- Insurance Funds	He fo	rustee- ld Funds r Capital Projects		Board- esignated Funded epreciation		Restricted by Donor	D	Board esignated Other	Total
						(In	Thousands)		-			
Pooled, Common and Collective Fund:						•						
Parametric Defensive Equity Fund LLC	\$	16,445	\$ -	\$	-	\$	-	\$	-	\$	-	\$ 16,445
Lord Abbett Core Fixed Income Fund		21,710	-		-		-		-		-	21,710
Lord Abbett Short Duration Income Fund		21,852	-		-		-		-		-	21,852
Clarion Lion Properties Fund		4,402	-		-		-		-		-	4,402
Total Pooled Investments		64,409	-		-		-		-		-	64,409
Total Direct and Pooled Investments	\$	337,733	\$ 229	\$	-	\$	26,734	\$	5,671	\$	2,650	\$ 373,017

Notes to Financial Statements

Note 3. Investments and Assets Whose Use is Limited (Continued)

The composition of investments in the Halifax Pension Plan at September 30, 2023, is set forth in the following table (in thousands):

Money market funds	\$ 989
Pooled, Common and Collective Fund:	
Parametric Defensive Equity Fund LLC	33,826
Lord Abbett Short Duration Credit Trust II Fee Class MQ	29,730
Lord Abbett Core Fixed Income Trust II Fee Class MQ	29,531
Clarion Lion Properties Fund	16,375
Partners Group Private Credit Strategy A LLC	19,479
Mutual funds:	
Chartwell Short Duration High Yield	12,412
DFA Emerging Markets Core Portfolio	14,190
DFA Large Cap International Portfolio	33,505
DFA U.S. Large Cap Value Portfolio	14,149
DFA U.S. Small Cap Value Portfolio	12,158
Vanguard Global Minimum Volatility Shares	32,594
Vanguard Growth Index Fund	12,090
Vanguard Total Stock Market Index Fund	47,003
Vanguard Short-Term Investment Grade Inst Fund	286
Vanguard Small Cap Growth Index Fund	6,842
Total	\$ 315,159

Assets whose use is limited for obligations classified as current liabilities are reported as current assets.

The Medical Center invests in money market, mutual funds and commingled investment vehicles whose underlying holdings qualify as fixed-income, equity or option securities in accordance with its investment policy described in Note 4.

At September 30, 2023, the Medical Center was invested in two money market funds, Wells Fargo Advantage Government Fund and Goldman Sachs Treasury Obligation Fund, and the following bond mutual funds:

- Vanguard Short-Term Investment Grade (VFSIX) actively invests its portfolio in short- and intermediate-term investment grade bonds. The fund had an average duration of 2.6 years as of September 30, 2023.
- Chartwell Short Duration High Yield Fund (CWFIX) actively invests in higher quality, short-term high yield corporate debt securities. The fund had an average duration of 2.1 years as of September 30, 2023.

At September 30, 2023, the Medical Center held debt securities in U.S. Treasury Obligations and U.S. Government-sponsored enterprises including Federal National Mortgage Association, Federal Home Loan Bank, and Federal Home Loan Mortgage Corporation.

Notes to Financial Statements

Note 3. Investments and Assets Whose Use is Limited (Continued)

Halifax holds the following Pooled Investment Funds:

- Parametric Defensive Equity Fund LLC is a commingled investment vehicle that provides income
 through selling call and put options on the S&P 500 while overlaying with positions in the S&P 500
 and in short-term U.S. treasury bills.
- The Clarion Lion Properties Fund is a core, open-end real estate fund that invests primarily in a diversified portfolio of high-quality real estate assets in the four main property types (office, retail, industrial and apartment) located in major markets across the United States.
- Lord Abbett Short Duration Income actively invests its portfolio in short-term investment grade bonds. The fund had an average duration of 1.9 years as of September 30, 2023.
- Lord Abbett Core Fixed Income actively invests its portfolio in investment grade bonds. The fund had an average duration of 5.9 years as of September 30, 2023.
- Partners Group Private Credit Fund seeks to generate attractive risk-adjusted returns and current
 income by investing in a diversified portfolio of primarily senior secured loans. The majority of Fund
 Investments will be the most senior tranche in the capital structure of the relevant borrowers and
 often have lien security over the assets of the borrowers. The Investments may also comprise of
 opportunistic credit, which may appear attractive on a relative value basis.

Investment gains on assets whose use is limited, restricted assets, and investments for the year ended September 30, 2023, was \$21.5 million and includes a favorable increase in unrealized gains and losses of \$7.7 million. Investment gains of the Foundation was \$5.4 million and includes a favorable increase in unrealized gains and losses of approximately \$3.7 million and is included in other operating revenue.

Note 4. Deposits and Investment Risk

GASB Cod. Sec. I50, *Investments*, requires disclosures related to investment and deposit risks, including risks related to credit risk, consisting of custodial credit risk and concentrations of credit risk, interest rate risk, and foreign currency risk. GASB Cod. Sec. I50 also requires the disclosure of the credit quality of investments in debt securities, except for obligations of the U.S. Government or obligations explicitly guaranteed by the U.S. Government.

<u>Investment Risk</u>: Investment policies were established in order to control and diversify risk by limiting specific security types and/or concentration with individual financial institutions. Specific investment types are limited to a percentage of the total investment portfolio and maximum maturity date. Investment strategies are influenced by relative market yields and the cash needs of Halifax Health. Excess funds of the Medical Center and its component units may be invested in accordance with the respective investment policies. Excess funds of the Medical Center may be invested in, but are not limited to:

- U.S. Government securities and repurchase agreements;
- U.S. Government agency and U.S. Government-sponsored enterprises;
- Domestic bank certificates of deposit provided that any such investments are in Federal Deposit Insurance Corporation guaranteed accounts or deposits collateralized by U.S. Government securities or obligations;
- Securities of, or other interests in, any management-type investment company or investment trust
 registered under the Investment Company Act of 1940, as amended from time to time, provided that
 the portfolio of such investment company or investment trust is limited to obligations of the
 U.S. Government or any agency or instrumentality thereof;

Notes to Financial Statements

Note 4. Deposits and Investment Risk (Continued)

- Repurchase agreements with reputable financial institutions, which are fully secured by U.S. Government obligations;
- Mutual funds of registered investment advisors may be purchased to invest in the permissible securities listed above; and
- Commingled investment vehicles holding permissible securities listed above and in strategies listed in accordance with the investment policy.

The Halifax Pension Plan's investment policy provides guidelines for the types of investments that can be acquired in order to provide maximum diversity and reduce risk. Specific asset classes are limited to a percentage of the total investment portfolio. Specific investment strategies are influenced by relative market yields and the cash needs of the Halifax Pension Plan. The Halifax Pension Plan may be invested in, but not limited to:

- Local government investment pool;
- U.S. Government securities and repurchase agreements;
- U.S. Government agency and U.S. Government-sponsored enterprises;
- Domestic Bank Certificates of Deposit provided that any such investments are in Federal Deposit Insurance Corporation ("FDIC") guaranteed accounts or deposits collateralized by U.S. Government securities or obligations;
- Repurchase agreements with reputable financial institutions, which are fully secured by U.S. Government obligations;
- Commercial Paper and Stocks; limited to issuers with an A rating or better;
- Mutual funds of registered investment advisors may be purchased to invest in the permissible securities listed above; and
- Commingled investment vehicles holding permissible securities listed above and in strategies listed in accordance with the investment policy.

All investment decisions are made based on reasonable research as to credit quality, liquidity, and counterparty risk prior to the investment. An investment advisory firm is utilized to monitor the investment of all funds and quarterly performance of the portfolio is reported to management and the Investment Committee of the Board.

<u>Custodial Credit Risk</u>: Custodial credit risk is the risk that, in the event of the failure of a depository financial institution, Halifax Health and the Halifax Pension Plan will not be able to recover its deposits. At September 30, 2023, Halifax Health and the Halifax Pension Plan's deposits, consisting primarily of cash and cash equivalents, were covered by federal depository insurance, collateralized with U.S. Treasury Securities and Federal agency securities or guaranteed 100% by the State of Florida and collateralized through the Florida Bureau of Collateralization.

Notes to Financial Statements

Note 4. Deposits and Investment Risk (Continued)

<u>Credit Risk</u>: The investment policy provides guidelines to investment managers that restrict investments in debt securities to those with an A- or A rating or better for Halifax Health and the Halifax Pension Plan, respectively, and established asset allocation limits to reduce the concentration of credit risk. Guidelines are provided to investment managers and monitored by the investment advisory firm and management for compliance. As of September 30, 2023, Halifax Health has an investment in debt securities with Federal National Mortgage Association totaling approximately \$9.0 million, representing 2.91% of total investments. At September 30, 2023, the money market fund held by Halifax Health had a credit rating of Aaa-mf, and other debt securities were limited to one fixed income commingled investment trust with credit ratings of underlying debt securities ranging from A3 to Baa3 from Moody's Investor Service.

As of September 30, 2023, the Halifax Pension Plan did not have investments in debt securities in any one issuer that represents 5% or more of the Halifax Pension Plan's fiduciary net position. The Halifax Pension Plan's investment in a mutual fund that primarily invests in debt securities have a credit rating of Aaa-mf from Moody's Investor Service.

<u>Interest Rate Risk</u>: Changes in interest rates can adversely affect the fair value of an investment. Halifax Health and the Halifax Pension Plan manage exposure to interest rate risk by limiting investment maturities and diversifying its investment portfolios.

As of September 30, 2023, Halifax Health had investments, assets whose use is limited and restricted assets maturing as follows:

			N	o Maturity Date or				
			L	ess than		1 – 5		6 – 10
	F	air Value		1 Year		Years		Years
				(In Tho	usand	ds)		
Money market funds	\$	2,668	\$	2,668	\$	-	\$	-
Mutual funds		126,299		126,299		-		-
U.S. Government securities		86,569		37,153		28,278		21,138
U.S. Government-sponsored								
enterprises		29,292		17,705		6,933		4,654
Corporate bonds		61,543		25,899		35,205		439
Other	2,237 2,237							-
Total	\$	308,608	\$	211,961	\$	70,416	\$	26,231
			N.	- M-4it				
			IN	o Maturity Date or				
				ess than		1 – 5		6 – 10
	Not	Asset Value	L	.ess than 1 Year		Years		6 – 10 Years
	ivet	Asset value						rears
Declar Common and Callective Funds				(In Tho	usanc	18)		
Pooled, Common and Collective Fund:	Φ.	40 445	Φ	10 115	Φ		Φ.	
Parametric Defensive Equity Fund LLC	\$	16,445	\$	16,445	\$	-	\$	-
Lord Abbett Core Fixed Income Fund		21,710		21,710		-		-
Lord Abbett Short Duration Income Fund		21,852		21,852		-		-
Clarion Lion Properties Fund		4,402		4,402		-		
Total	\$	64,409	\$	64,409	\$	-	\$	

At September 30, 2023, all of the Halifax Pension Plan's investments had maturity dates within one year or no maturity date.

Notes to Financial Statements

Note 5. Capital Assets and Right to Use Lease Assets

Capital assets and right to use lease assets are presented net of accumulated depreciation and amortization, respectively, in the accompanying statement of net position. A summary of the activities for the year ended September 30, 2023, is presented below:

	Balance at September 30, 2022 Increases			Decreases	S	Balance at September 30, 2023	Elimination Entries	Balance at ptember 30, 2023	
Depreciable capital assets:									
Land improvements	\$	8,668	\$	8	\$ (67)	\$	8,609	\$ -	\$ 8,609
Buildings		530,616		6,815	(2,066)		535,365	-	535,365
Fixed equipment		35,640		1,039	(728)		35,951	-	35,951
Major moveable equipment		104,933		8,749	(3,961)		109,721	-	109,721
Computers and software		32,052		3,023	(1,836)		33,239	-	33,239
Accumulated depreciation		(359,188)		(27,215)	8,062		(378,341)	-	(378,341)
Depreciable capital assets-net		352,721		(7,581)	(596)		344,544	-	344,544
Nondepreciable capital assets:									
Land		50,089		4,289	(591)		53,787	-	53,787
Projects in progress		12,639		59,236	(19,073)		52,802	-	52,802
Capital assets-net	\$	415,449	\$	55,944	\$ (20,260)	\$	451,133	\$ -	\$ 451,133
Right to use assets									
Buildings and leasehold improvements	\$	16,658	\$	535	\$ (5)	\$	17,188	\$ -	\$ 17,188
SBITAs		-		20,534	-		20,534	-	20,534
Accumulated amortization - SBITAs		-		(5,184)	-		(5,184)	-	(5,184)
Accumulated amortization - leases		(2,449)		(6,259)	-		(8,708)	(3,980)	(4,728)
Right to use assets, net	\$	14,209	\$	9,626	\$ (5)	\$	23,830	\$ (3,980)	\$ 27,810

Note 6. Self-Insurance and Insurance

<u>Self-Insurance</u>: The Medical Center is self-insured for various risks of loss, including professional and general liability losses, workers' compensation claims, and employees' health claims. Certain component units participate in the Medical Center's employee health and workers' compensation self-insurance programs. Self-insurance funds are held by a trustee bank and recorded as assets whose use is limited.

The Medical Center, as a subdivision of the State of Florida, has sovereign immunity in tort actions. Therefore, in accordance with Chapter 768.28, Laws of Florida, the Medical Center and its component units are not liable to pay a claim by or judgment to any one person which exceeds the sum of \$200,000 or any claim or judgment, or portions thereof, which when totaled with all other claims or judgments paid by the state or its agencies or subdivisions arising out of the same incident or occurrence exceeds the sum of \$300,000. Chapter 768.28 also provides that judgments may be claimed or rendered in excess of these limits; however, these amounts must be reported to and approved by the Florida Legislature.

Professional and general liability losses are recorded when it is probable that a loss has occurred and the amount of that loss can be reasonably estimated. Accrued self-insurance liabilities include an amount for claims that have been incurred but not reported based on actuarial determinations. Because actual claim liabilities depend on such complex factors as inflation, changes in legal doctrines, and damage awards, the process used in computing claim liabilities does not necessarily result in actual claim amounts. Claims liabilities are reevaluated periodically to take into consideration recently settled claims, the frequency of claims, and other economic and social factors. Due to current economic factors, the Medical Center discount rate is 2% and the confidence level is 95% as of September 30, 2023.

Notes to Financial Statements

Note 6. Self-Insurance and Insurance (Continued)

The liabilities for employees' health insurance and workers' compensation claims are estimated based on historical data. The Medical Center has commercial insurance policies for health insurance and workers' compensation for cases that exceed certain limits. The health insurance policy includes an 80% indemnity of cases that exceed \$325,000 and a \$1 million lifetime maximum. Specific excess coverage for workers' compensation includes retention of \$750,000 per incident.

Changes in the accrued self-insurance liabilities for the years ended September 30, 2023 and 2022, are as follows:

	 alance at tember 30, 2022	CI Cł	rrent Year aims and nanges in stimates	P	Claim ayments	_	alance at tember 30, 2023
Employee health Professional liability Workers' compensation Total	\$ 1,550 10,800 3,610 15,960	\$	4,741 (1,691) 135 3,185	\$	(4,941) (409) (1,045) (6,395)	\$	1,350 8,700 2,700 12,750
	 alance at tember 30, 2021	CI Cł	rrent Year aims and nanges in stimates	P	Claim ayments		alance at tember 30, 2022
Employee health Professional liability Workers' compensation Total	\$ 1,550 12,150 3,250 16,950	\$	5,934 (723) (1,017) 4,194	\$	(5,934) (627) 1,377 (5,184)	\$	1,550 10,800 3,610 15,960

Certain matters of litigation against Halifax Health arise in the normal course of business. Losses in excess of amounts accrued may occur although an estimate of such excess cannot be made. It is the opinion of management that the ultimate liability, if any, resulting from these matters will not have a material adverse effect on Halifax Health's financial statements.

Notes to Financial Statements

Note 7. Agreements

Master Securities Loan Agreement: MCD entered into a MSLA with JPMC. MCD and JPMC are the only parties to the MSLA. Under the terms and conditions of the MSLA, JPMC is obligated to make payments to MCD equal to the actual interest paid on the 2019 and Series 2022-MCD Bonds in exchange for payments from MCD based upon the outstanding par amount of the 2019 and Series 2022-MCD Bonds and a variable index rate (regularly scheduled payments). The MSLA has a scheduled termination date of December 18, 2026. Upon the occurrence of certain events, both MCD and JPMC maintain early termination rights by giving notice to the other party prior to the close of business on a business day. Upon any scheduled, unscheduled, or optional termination, MCD is obligated to pay JPMC the fair value of the 2019 and Series 2022-MCD Bonds as of the termination date in addition to any regularly scheduled payments due. Both the asset and obligation in the amount of \$132.1 million are recorded on the statement of net position as of September 30, 2023.

Management Services, Governance, and Contribution Agreement: On December 17, 2019, MCD entered into a Management Services, Governance, and Contribution Agreement ("Agreement") with the Medical Center, HMS, and Hospice, as well as Shands Teaching Hospital and Clinics, Inc. ("Shands"). Under the Agreement, the Medical Center and Shands will: (i) provide management services to operate the Medical Center of Deltona, (ii) provide equal capital funding contributions, and (iii) equally receive MCD profits and distributions. On February 2, 2022, MCD entered into an amendment to the Agreement. Under the amendment, MCD issued the Series 2022, Hospital Revenue Bonds in the amount of \$14.5 million to finance the acquisition of the emergency room facilities located on MCD's campus in the City of Deltona. Additionally, under the Agreement and 2022 amendment, Shands, HMS, and Hospice agreed to individually provide (and have provided) joint and several liability guarantees for the obligations under the MSLA. In accordance with the agreement, in December 2022 the capital funding contribution from Shands in the amount of \$12 million was released from noncurrent liabilities and reflected as a contribution in the statement of revenues, expenses and change in net position.

Note 8. Long-Term Debt

Long-term debt at September 30, 2023, consists of the following:

	С	urrent			
	Po	rtion of	L	ong-Term	
	Long-	Term Debt		Debt	Premium
			(In	Thousands)	
Bonds payable:					
Series 2008	\$	-	\$	70,000	\$ -
Series 2015		5,555		5,820	984
Series 2016		1,490		154,325	7,450
Series 2019		2,025		115,550	-
Series 2022 - MCD		-		14,490	-
Series 2022 - Medical Center		565		79,065	-
Total bonds payable	\$	9,635	\$	439,250	\$ 8,434

Notes to Financial Statements

Note 8. Long-Term Debt (Continued)

<u>Bonds Payable</u>: Halifax Health has \$448.9 million of outstanding debt, which was issued to refund prior debt and to provide funding for capital projects and operating reserves. The debt is organized with outstanding principal balances as follows: \$70 million of tax-exempt, variable-rate demand-obligation ("VRDO") bonds ("Series 2008"), secured by a letter of credit; \$11.4 million of tax-exempt, fixed rate bonds ("Series 2015"), \$155.8 million of tax-exempt, fixed rate bonds ("Series 2016"), \$117.6 million of revenue bonds ("Series 2019"), \$79.6 million of taxable refunding bonds ("Series 2022-Halifax) and \$14.5 million of revenue bonds ("Series 2022 – MCD").

Pursuant to the terms of the Master Trust Indenture ("MTI") and First Amendment under which the Series 2008, 2015, 2016, and 2022 Halifax Health bonds were issued (excluding conduit indebtedness), principal and interest on each bond series are payable from and secured by a pledge of net revenues of the Obligated Group. The members of the Obligated Group are the Medical Center and Holdings. In accordance with generally accepted accounting principles, certain component units are blended with the accounts of the Medical Center in the Obligated Group's financial information, including EVHS, Staffing, HHCSI and PBFS.

The Series 2022 MCD Bonds were issued at par value with a 5.00% interest rate coupon and may be redeemed at the option of the Borrower. The Series 2022 bonds have a maturity date of December 15, 2049, and are secured by a mortgage on the assets of MCD.

The Series 2019 Bonds were issued at par value with a 5.25% interest rate coupon and may be redeemed at the option of MCD in whole or in part beginning on December 15, 2020, at 100% of the principal amount to be redeemed plus accrued interest to the redemption date. The Series 2019 bonds have a maturity date of December 15, 2049, and are secured by a mortgage on the assets of MCD.

The Series 2015 bonds and Series 2016 bonds have maturities extending through 2046. Interest rates range from 3.0% to 5.0%.

The Series 2008 bonds are tax-exempt, variable-rate securities with a weekly interest-rate period. The Series 2008 bonds have final maturities of June 1, 2048, subject to the demand provisions described below. The net proceeds of the Series 2008 bonds were used to advance refund a portion of the Medical Center's outstanding indebtedness, to provide funds for future capital projects, and for reimbursement of prior capital expenditures.

The Series 2008 bonds are subject to purchase from time to time at the option of the owners thereof and are required to be purchased in certain circumstances. As such, the bonds are supported by a remarketing agreement and an irrevocable direct pay letter of credit with a bank in the aggregate amount of \$70 million at September 30, 2023. The remarketing agreement generally provides the Medical Center the option to market the obligations at the then-prevailing short-term rate, as determined by the remarketing agent. The obligations were marketed weekly during 2023, with interest rates ranging from 1.65% to 4.47%. The term of the letter of credit expires November 5, 2028. The letter of credit is secured by an interest in any bonds purchased with draws on the letter of credit and amounts payable under the MTI. The Medical Center did not draw on the letter of credit during 2023. In the event that the Series 2008 bonds are unable to be remarketed, the Medical Center would be required to draw on the letter of credit. Repayments of principal and interest would begin 367 days after the date of the draw (and no draw may be made on the letter of credit without seven days written notice). Repayments will be made in 12 equal quarterly installments of principal plus interest. Therefore, the final quarterly installment to be made under the provisions of the letter of credit would occur on July 10, 2026. Pursuant to the terms of the letter of credit, the Medical Center is required to comply with certain provisions regarding additional borrowings, capital expenditures, and the maintenance of certain financial ratios.

Notes to Financial Statements

Note 8. Long-Term Debt (Continued)

The Medical Center has a \$70 million notional-amount fixed-pay percentage of the London InterBank Offered Rate ("LIBOR") interest rate swap on the Series 2008 bonds (the "Swap"). The variable interest paid on the Series 2008 bonds is expected to correlate very closely with the rate that is received on the related Swap. In accordance with the adoption of GASB No. 93, the Medical Center transitioned from LIBOR to the Secured Overnight Financing Rate ("SOFR") effective July 2023. The effective interest rate on the Swap is a synthetic fixed rate of interest of 3.90% at September 30, 2023. See Note 9 for further information on the Swap.

The Obligated Group is required to comply with certain provisions regarding additional borrowings and the maintenance of certain minimum debt service coverage, liquidity, and indebtedness ratios. A summary of bond issues follows (in thousands):

Fixed Rate Bonds

Tixed Rate Bollas				Term Bonds	S			Serial Bonds	
	Date Issued/	Ori	ginal Issue	Interest	Maturity	Ori	iginal Issue	Interest	Maturity
Series	Converted		Amount	Rate	Date		Amount	Rate	Date
Series 2015	April 29, 2015					\$	57,530	4.00%-5.00%	June 1, 2046
Series 2016	March 28, 2016	\$	48,430	5.00	June 1, 2030	\$	117,060	3.38%-5.00%	June 1, 2046
				3.38	June 1, 2031				
				5.00	June 1, 2036				
				3.75	June 1, 2041				
				4.00	June 1, 2046				
Series 2019	December 18, 2019	\$	123,055	5.25	December 15, 2049				
Series 2022 - Medical Center	March 15, 2022	\$	80,185	2.58%	June 1, 2025				
				2.11%	June 1, 2046				
Series 2022 - MCD	February 2, 2022	\$	14,490	5.00%	December 15, 2049				
Variable-Rate Bonds									
				Interest					
				Rate at			Interest		
	Date	Ori	ginal Issue	September 30,	Maturity		Rate		
Series	Issued		Amount	2023	Date		Period	_	
Series 2008	September 18, 2008	\$	70,000	3.639%*	June 1, 2048		7 days		

^{*} This rate is the remarketed interest rate in effect as of September 30, 2023. The Medical Center also has a fixed-pay interest rate as part of the Swap. See Note 9 for more information on the Swap.

Notes to Financial Statements

Note 8. Long-Term Debt (Continued)

Listed below are the debt service payments for Halifax Health for each of the five years ending September 30, 2024 through 2028 and in five-year increments thereafter (in thousands). The principal shown on the Series 2008 bonds is based on scheduled repayments. The interest rate used to calculate interest on the Series 2008 bonds was the remarketed interest rate in effect at September 30, 2023. The table below excludes interest amounts related to the swap (see Note 9).

																						Total Debt	Secu	ured by		T	otal					
		Serie	es 20	08		Serie	s 20	15		Serie	s 201	16	Sei	ries 2022 (N	1edic	al Center)		Serie	s 201	19		Series 20)22 (I	MCD)		Obligate	d Gr	oup		Halifa	к Неа	lth
	F	Principal		Interest	F	Principal		Interest	F	Principal		Interest	F	Principal		nterest	F	Principal		Interest	F	rincipal		nterest	Р	rincipal		Interest	F	Principal	I	nterest
2024	\$	-	\$	2,870	\$	5,555	\$	569	\$	1,490	\$	6,828	\$	565	\$	2,066	\$	2,025	\$	6,120	\$	-	\$	725	\$	7,610	\$	12,333	\$	9,635	\$	19,178
2025		-		2,870		5,820		291		1,580		6,753		580		2,033		2,135		6,010		280		718		7,980		11,947		10,395		18,675
2026		-		2,870		-		-		1,650		6,674		7,085		1,651		2,250		5,895		295		703		8,735		11,195		11,280		17,793
2027		-		2,870		-		-		6,165		6,592		2,805		1,507		2,375		5,774		310		688		8,970		10,969		11,655		17,431
2028		-		2,870		-		-		6,460		6,283		2,875		1,447		2,500		5,646		325		672		9,335		10,600		12,160		16,918
2029-2033		-		14,350		-		-		37,285		26,482		15,260		6,302		14,675		26,055		1,880		3,093		52,545		47,134		69,100		76,282
2034-2038		-		14,350		-		-		47,030		16,726		16,950		4,623		19,075		21,651		2,415		2,560		63,980		35,699		85,470		59,910
2039-2043		24,220		11,451		-		-		31,100		8,203		21,085		2,734		24,810		15,922		3,105		1,875		76,405		22,388		104,320		40,185
2044-2048		45,780		4,867		-		-		23,055		1,868		12,425		528		32,260		8,472		3,985		992		81,260		7,263		117,505		16,727
2049-2050		-		-		-		-		-		-		-		-		15,470		823		1,895		96		-		-		17,365		919
Total	\$	70,000	\$	59,368	\$	11,375	\$	860	\$	155,815	\$	86,409	\$	79,630	\$	22,891	\$	117,575	\$	102,368	\$	14,490	\$	12,122	\$	316,820	\$	169,528	\$	448,885	\$	284,018

Notes to Financial Statements

Note 8. Long-Term Debt (Continued)

Long-term debt (and related premium) activity for the year ended September 30, 2023, consisted of the following:

	Sep	alance at otember 30, 2022 des Premium)	Additions	Reductions by Payments or Decreases	S	Balance at September 30, 2023	Due Within One Year
Series 2008	\$	70,000	\$ _	\$ -	\$	70,000	\$ -
Series 2015		18,234	-	(5,875)		12,359	5,555
Series 2016		165,022	-	(1,757)		163,265	1,490
Series 2019		119,500	-	(1,925)		117,575	2,025
Series 2022 (MCD)		14,490	-	-		14,490	-
Series 2022 (Medical Center)		80,185	-	(555)		79,630	565
Total	\$	467,431	\$ -	\$ (10,112)	\$	457,319	\$ 9,635

Note 9. Interest Rate Swap

The Medical Center has entered into a Swap agreement with a notional amount of \$70 million in conjunction with the issuance of the Series 2008 bonds that effectively converts the variable rate bonds to a fixed rate. Under the terms of the Swap, the Medical Center pays to the counterparty a fixed rate of interest equal to 3.837% of the remaining notional amount. In turn, the Medical Center receives a payment of variable interest. As of July 2023, the variable interest is calculated based on SOFR. The termination date of this Swap agreement is June 1, 2048, which coincides with the maximum maturity of the Series 2008 bonds. Payments under the Swap agreement are insured by Assured Guaranty Municipal Corp. ("AGMC"). For the year ended September 30, 2023, the Medical Center made approximately \$2.7 million in payments under the Swap agreement to the counterparty and received approximately \$2.1 million in payments under the Swap agreement from the counterparty. The payments made and received under the Swap agreement are included in interest expense on the accompanying statement of revenues, expenses and changes in net position.

In accordance with GASB Cod. Sec. D40, the Medical Center applies hedge accounting for its Swap. At September 30, 2023, the fair value of the Swap liability of approximately \$8.3 million was included in other long-term liabilities, with the current-year change in fair value of approximately \$5.4 million recorded as a decrease in deferred outflows. The fair value of the Swap was approximately \$8.3 million at September 30, 2023, as determined by an independent source. In accordance with GASB Statement No. 72, the fair value measurement of the Swap is classified as Level 2 and is valued using matrix pricing based on the securities' relationship to benchmark quoted prices.

<u>Interest Rate Risk</u>: The Medical Center is exposed to interest rate risk on the Swap. As SOFR decreases, the Medical Center's net payment on the Swap increases.

Notes to Financial Statements

Note 9. Interest Rate Swap (Continued)

<u>Basis Risk</u>: The Medical Center is exposed to basis risk on the Swap because the variable-rate interest payments it receives on the Swap is based on a rate other than the interest rate the Medical Center pays on its hedged, variable rate debt, which is remarketed every seven days. As of September 30, 2023, the interest rate on the hedged variable-rate debt is 4.10% and 70% of SOFR is 3.64%.

<u>Termination Risk</u>: The Medical Center or its counterparty may terminate the Swap if the other party fails to perform under the terms of the agreement. If, at the time of termination, the Swap is in a liability position, the Medical Center would be liable to the counterparty for payment equal to the liability, subject to net settlement.

The following table summarizes the Medical Center's anticipated net cash flows from outstanding variable rate debt and the related Swap at September 30, 2023 (in thousands). The interest rates used to calculate interest on the variable rate debt and the variable portion of the Swap were the respective interest rates in effect at September 30, 2023. The rate used for the fixed-pay portion of the Swap is the actual interest rate of 3.837%.

			1	Net Interest	Total
	Principal	Interest		on Swap	Interest
Years ending September 30:					
2024	\$ -	\$ 2,870	\$	139	\$ 3,009
2025	-	2,870		139	3,009
2026	-	2,870		139	3,009
2027	-	2,870		139	3,009
2028	-	2,870		139	3,009
2029-2033	-	14,350		693	15,043
2034-2038	-	14,350		693	15,043
2039-2043	24,220	11,451		553	12,004
2044-2048	45,780	4,867		235	5,102
Total	\$ 70,000	\$ 59,368	\$	2,869	\$ 62,237

Note 10. Pension Plan

<u>Defined Benefit Pension Plan</u>: Certain employees participate in the Halifax Pension Plan, which is a cost-sharing, multiple-employer, noncontributory defined benefit pension plan (the "Plan") with two participating employers, Staffing and Hospice. The Plan is treated as a single employer plan for the purposes of making contributions and paying pension benefits, determining whether there has been any termination of service, and applying the maximum benefit limitation. Plan provisions are established and may be amended by the Board of Staffing, the Plan's sponsor. The Plan issues stand-alone financial statements that can be obtained by contacting the Plan's sponsor or by accessing Halifax Health's website at www.halifaxhealth.org. The Plan's financial statements are prepared using the accrual basis of accounting.

Notes to Financial Statements

Note 10. Pension Plan (Continued)

The Plan covers all eligible employees who have attained the age of 21 and have more than one year of service. Eligibility for the Plan was closed to all employees whose initial hire date or rehire date was on or after October 1, 2000. Halifax Health assumed the unfunded portion of the past service liability for employees who participated and were not vested in the prior pension benefit programs. As of September 30, 2022, the measurement date, the Plan included 217 active employees, 324 terminated but vested participants, and 1,016 retired participants and beneficiaries.

Pension plan benefits are based on the number of years of service and the employee's highest three-year average annual compensation. Effective October 1, 2013 the Plan was frozen and as such, participants of the Plan will no longer accrue credit for years of service and, upon eligibility, calculation of benefits will be made based on compensation information through October 1, 2013. Participants may elect to receive pension plan benefits as a monthly annuity or as one lump-sum payment for an amount equal to the present value of future benefits, as calculated by an actuary. Beneficiaries receive an annual, automatic 3% cost of living adjustment.

The Medical Center is obligated by a contractual agreement to fund contributions on behalf of Staffing. The contribution rate is determined on an actuarial basis. Halifax Health contributed \$16.6 million to the Plan in fiscal year 2023. In accordance with GASB Statement No. 68, that amount is recorded on the statement of net position as a deferred outflow at September 30, 2023. The Medical Center's proportionate share of the contribution, expense and net pension liability is 94.19% and Hospice's proportionate share is 5.81% for fiscal year 2023. The proportionate share calculation is based on the present value of future salaries for active employees of Staffing and Hospice.

Significant assumptions of the Plan are presented in the following table:

Actuarial Methods and Assumptions

Mortality table Pri-2012 Mortality Table (Sex-Distinct), Scale MP-2021

Interest rate 6.375% annually, compounded

Pay increase N/A Cost of living adjustment 3%

Measurement date

Valuation date

October 1, 2022

Allocation of Plan assets

September 30, 2022

October 1, 2022

55-75% Equities

20-40% Fixed income

0-7% Core Private Real Estate

0-7% Private Credit

Real rate of return Overall – +11.6%, arithmetic mean

Equities – +19.4% Fixed income – +3.6% Real Estate – (17)% Private Credit – +12.9%

Experience study date October 1, 2021

Notes to Financial Statements

Note 10. Pension Plan (Continued)

The discount rate used in measuring the total net pension liability of \$60.3 million was 6.375% for fiscal year 2023. The long-term expected rate of return on plan assets is 6.375%. The discount rates and rate of return are based on the long-term rate of return on pension plan investments expected to finance the payment of benefits into the future. Net pension liability at September 30, 2023, using a discount rate of 5.375% would have been \$97.2 million, and using a discount rate of 7.375% would have been \$28.8 million.

The long-term expected rate of return on pension plan investments was determined using a building-block method in which best-estimate ranges of expected future real rates of return (expected returns, net of pension plan investment expense and inflation) are developed for each major asset class. These ranges are combined to produce the long-term expected rate of return by weighting the expected future real rates of return by the target asset allocation percentage and by adding expected inflation. The target allocation and best estimates of arithmetic real rates of return for each major asset class are summarized in the table on the previous page.

The projection of cash flows used to determine the discount rate assumed that contributions from the Medical Center and Hospice will continue into the future and that the Plan will eventually be fully funded. It is assumed that 25% of participants will elect a one-time, lump-sum benefit upon termination, and 0% of participants will elect a one-time, lump-sum benefit payment upon retirement. Based on those assumptions, the pension plan's fiduciary net position was projected to be available to make all projected future benefit payments of current active and inactive employees. Therefore, the long-term expected rate of return on pension plan investments was applied to all periods of projected benefit payments to determine the total pension liability.

The net pension liability at September 30, 2023, using a discount rate of 6.375%, was \$60.3 million. Since the last measurement date, September 30, 2022, the Plan updated its assumptions using the PRI-2012 (sex-distinct) table for employees and healthy annuitants with mortality improvements projected using Scale MP-2021 on a fully generational basis.

Notes to Financial Statements

Note 10. Pension Plan (Continued)

Changes in the pension accounts since the last valuation date, and pension expense, are as follows (in thousands):

		red Outflow - Pension Intributions	(Infl	Deferred ow)/Outflow - stment Returns		erred Outflow - iability Loss		erred Outflow - Change in Assumptions		otal Pension Liability		an Fiduciary et Position	N	Net Pension Liability		Pension Expense
Balance at September 30, 2022	\$	21,315	\$	(15,073)	\$	_	\$	_	\$	(373,542)	\$	348,042	\$	(25,500)	\$	-
Service cost	,	-	,	-	·	-	·	-	·	(1,661)	•	-	•	(1,661)	•	1,661
Interest cost		_		-		-		-		(22,874)		_		(22,874)		22,874
Difference in expected and										, , ,				(, ,		,
actual experience		_		58,769		(8,950)		_		8,950		(58,769)		(49,819)		-
Changes of assumptions		_		, -		-		4,213		(4,213)		-		(4,213)		-
Projected investment income		-		_		-		-		,		22,491		22,491		(22,491)
Benefit payments		-		_		-		_		47,331		(47,331)		-		-
Expenses		-		_		-		_		_		(41)		(41)		41
Contributions recognized in												, ,		, ,		
Plan fiduciary net position		(21,315)		-		-		-		-		21,315		21,315		-
Contributions made after		, ,														
measurement date		16,600		-		-		_		-		-		-		-
Amortization of deferred balances		-		(11,213)		8,950		(4,213)		-		-		-		6,476
Balance at September 30, 2023	\$	16,600	\$	32,483	\$	-	\$	-	\$	(346,009)	\$	285,707	\$	(60,302)	\$	8,561
Proportionate share of the above balan Medical Center	ces as of	15,636	\$0, 2023 \$	30,596	\$	_	\$	-	\$	(325,906)	\$	269,107	\$	(56,798)	\$	8,064
Hospice		964		1,887		-		-		(20,103)		16,600		(3,504)		497
	\$	16,600	\$	32,483	\$	-	\$	-	\$	(346,009)	\$	285,707	\$	(60,302)	\$	8,561

Notes to Financial Statements

Note 10. Pension Plan (Continued)

The following table shows the balances of deferred inflows and outflows for the Plan as of September 30, 2023, the amount of deferred outflows to be realized in future years and the amount of deferred inflows to be recognized in future years' pension expense as follows (in thousands):

				Deferred			De	eferred		To Be
		Deferred		Outflow -		Deferred	Οι	utflow -	Red	cognized in
	C	Outflow -	li	nvestment		Outflow -	Ch	ange in	Futu	ıre Pension
	Co	ntributions		Returns	L	iability Loss	Ass	umptions		Expense
Balance at September 30:										
2023	\$	16,600	\$	32,483	\$	-	\$	-	\$	-
2024		(16,600)		(10,547)		-		-		10,547
2025		-		(5,841)		-		-		5,841
2026		-		(4,342)		-		-		4,342
2027		-		(11,753)		-		-		11,753
	\$	-	\$	-	\$	-	\$	-	\$	32,483

<u>Defined Contribution Pension Plan</u>: Eligible employees may participate in a 403(b) defined contribution pension plan (the "Contribution Plan"). The Contribution Plan covers all eligible employees who have attained the age of 18 and have completed 30 days of employment. Employee contributions are matched dollar-for-dollar up to 3% of annual salary. Employees vest 20% per year of employment for employer-matched funds.

Total expense of the Contribution Plan for the year ended September 30, 2023, was approximately \$6.9 million and is included in salaries and benefits in the accompanying statement of revenues, expenses and changes in net position. Participants contributed approximately \$13.0 million to the Contribution Plan for the year ended September 30, 2023.

Note 11. Other Postemployment Benefits

Other Postemployment Benefit Plans: Qualified retired employees are eligible for certain postretirement benefit plans other than pensions ("OPEB").

Retiree HRA Plan description: All employees with 10 years of benefited service as a participant in the Halifax Pension Plan or the Florida Retirement System are eligible to receive a subsidy for health insurance premiums ("Retiree HRA Plan"). The Retiree HRA Plan is a multi-employer defined benefit plan. The participant must present, at the time of retirement, evidence of health insurance coverage, either through an insurance company or Medicare. Contributions to the Retiree HRA Plan are calculated based on the number of years of service and is limited to a maximum annual benefit of \$1,800 per participant. The Retiree HRA Plan does not issue stand-alone financial statements. It is included in the financial statements and required supplementary information.

Retiree Medical Plan description: Health insurance is also offered as a continuation of retiree group health benefits to certain retirees. All employees with 10 years of benefited service as a participant in the Halifax Pension Plan or with 30 years of benefit service who elect coverage from benefit eligible, active employment are able to participate in the Retiree Medical Plan ("Retiree Medical Plan").

Retirees and spouses on or before October 1, 2017 (Grandfathered) receive benefit coverage for the life of the retiree, provided the retiree and spouse, if applicable, elect coverage under Medicare Parts B and D when first eligible.

Notes to Financial Statements

Note 11. Other Postemployment Benefits (Continued)

Retirees after October 1, 2017 may receive benefit coverage until attainment of age 65. Spouses of retirees after October 1, 2017, may receive benefit coverage until the earlier of attainment of age 65, the date the retiree reaches age 65 or the date the retiree ceases to be covered for any reason. There is no surviving spouse coverage under the plan.

The Retiree Medical Plan is a multi-employer defined benefit plan. Contributions to the Retiree Medical Plan are determined based on the calculated subsidized premium per participant. The Retiree Medical Plan does not issue stand-alone financial statements. It is included in the financial statements and required supplementary information.

<u>Employees Covered by Benefit Terms</u>: The following employees were covered by the benefit terms, as of October 1, 2022, which is the most recent actuarial valuation date:

	Retiree HRA Plan	Retiree Medical Plan
Active employees not fully eligible for benefits	148	106
Inactive employees currently receiving benefits	1,277	7
Active employees fully eligible for benefits	69	109
	1,494	222

<u>Actuarial Methods and Assumptions</u>: The total Retiree HRA Plan and Retiree Medical Plan's liabilities in the September 30, 2023 actuarial valuation were determined using the following actuarial assumptions and other inputs, applied to all periods included in the measurement, unless otherwise specified:

	Retiree HRA	Retiree Medical
Actuarial Methods and Assumptions	Plan	Plan
Reporting date	September 30, 2023	September 30, 2023
Measurement date	September 30, 2022	September 30, 2022
Actuarial valuation date	October 1, 2022	October 1, 2022
Discount rate	4.40%	4.40%
Rate of compensation increase	3.00%	3.00%
Health care cost trend rates	N/A	**
Inflation rate	2.25%	2.50%
Actuarial cost method	Entry Age Normal	Entry Age Normal
Amortization method	Level Percentage	Level Percentage
Amortization period	1.000	4.695
Method used to determine actuarial value of assets	N/A	N/A

^{** 6.75%} for health care costs, decreasing to an ultimate rate of 3.78% in 2075. 7.0% for prescription drugs, decreasing to an ultimate rate of 3.78% in 2075.

The discount rate was based on the Fidelity General Obligation 20-year AA Municipal Bond Index.

The actuarial assumptions used in the September 30, 2023 report were based on the results of an actuarial experience study for the period ended October 1, 2022. These actuarial assumptions are based on the presumption that the Retiree HRA Plan and the Retiree Medical Plan will continue. Actuarial valuations of an ongoing plan involve estimates of the value of reported amounts and assumptions about the probability of occurrence of events far into the future.

Notes to Financial Statements

Note 11. Other Postemployment Benefits (Continued)

Changes in the Retiree HRA Plan and the Retiree Medical Plan Liability:

	R	etiree HRA Plan	Reti	ree Medical Plan
			ousands)	
Balance as of October 1, 2022	\$	20,649	\$	1,005
Changes for the year:				
Service cost		186		2
Interest		445		20
Differences between expected and actual experience		(356)		(105)
Changes of assumptions or other inputs		(3,923)		9
Benefit payments		(1,004)		(197)
Net changes		(4,652)		(271)
Balance as of September 30, 2023	_ \$	15,997	\$	734

Changes of assumptions or other inputs reflect a change in the discount rate from 2.19% as of October 1, 2021 to 4.40% as of September 30, 2022.

Sensitivity of the Total OPEB Liability to Changes in the Discount Rate: The following table presents the total Retiree HRA Plan and Retiree Medical Plan OPEB liability of Halifax Health, as well as what the approximate total liability would be if it were calculated using a discount rate that is 1-percentage-point lower (3.40%) or 1-percentage-point higher (5.40%) than the current discount rate:

	1%	Decrease	Dis	count Rate	19	% Increase
		3.40%		4.40%		5.40%
			(In T	housands)		
Total Retiree HRA Plan liability	\$	17,605	\$	15,997	\$	14,617
Total Retiree Medical Plan liability		767		734		702

OPEB Expense and Deferred Outflows of Resources and Deferred Inflows of Resources Related to the OPEB: For the year ended September 30, 2023, Halifax Health recognized a Retiree HRA Plan expense in the amount of \$3.6 million and a credit to expense in the Retiree Medical Plan expense of \$94,000. At September 30, 2023, Halifax Health reported deferred outflows of resources and deferred inflows of resources related to the Retiree HRA Plan and Retiree Medical Plan from the following sources:

		Retiree	HRA P	lan		Retiree M	edical	Plan
	D	eferred	De	eferred	De	eferred	D	eferred
	Ou	tflows of	Infl	ows of	Out	flows of	In	flows of
	Resources		Res	sources	Res	sources	Re	sources
				(In The	ousands))		
Differences between expected and								
actual experience	\$	-	\$	_	\$	-	\$	(244)
Changes of assumptions or other inputs		-		_		15		(5)
Employer contributions subsequent to the								
measurement date		1,044		_		113		-
	\$	1,044	\$	-	\$	128	\$	(249)

Notes to Financial Statements

Note 11. Other Postemployment Benefits (Continued)

Employer contributions subsequent to the measurement date of October 1, 2022 of approximately \$1.0 million for the Retiree HRA Plan which is reported as deferred outflows of resources as of September 30, 2023, will be recognized as a reduction of the OPEB liability in Halifax Health's year ended September 30, 2023. Other amounts reported as the deferred outflows of resources and deferred inflows of resources related to the Retiree HRA Plan and Retiree Medical Plan will be recognized in OPEB expense future service to retirement of plan participants as follows:

	Retiree H	RA	Retire	ee Medical
	Plan		Plan	
	(Ir	1 Thou	usand	s)
Years ending September 30:				
2024	\$	-	\$	(124)
2025		-		(76)
2026		-		(20)
2027		-		(14)
	\$	-	\$	(234)

Note 12. Commitments and Contingencies

<u>Lessee Leases and SBITAs</u>: In connection with the adoption of GASB No. 96, Halifax Health recognized a SBITA liability and a right to use asset for agreements in which Halifax Health has the right to use another party's information technology software, alone or in combination with tangible capital assets for a period of one year or greater.

Lease activity for the year ended September 30, 2023, consisted of the following:

	l l	Balance at		Re	ductions	В	alance at		
	Se	ptember 30,		by F	Payments	Sep	otember 30,	Du	e Within
		2022	Additions	or D	ecreases		2023	O	ne Year
Lease liabilities	\$	14,489	\$ 535	\$	(2,079)	\$	12,945	\$	2,170

In connection with GASB No. 87, Halifax Health recorded a lease obligation and right to use asset for agreements in which Halifax Health has the right to determine the nature and manner of an underlying asset's use for a period of one year or greater.

SBITA activity for the year ended September 30, 2023, consisted of the following:

	Balai	nce at		Redu	uctions	Balance at	
	Septen	nber 30,		by Pa	yments	September 30,	Due Within
	20)22	Additions	or Dec	creases	2023	One Year
							-
SBITA liabilities	\$	- \$	20,534	\$	(4,846)	\$ 15,688	\$ 5,532

Notes to Financial Statements

Note 12. Commitments and Contingencies (Continued)

Future minimum SBITA (GASB No. 96) payments are as follows (in thousands):

	F	Principal	Interest	Total
Years ending September 30:				
2024	\$	5,532	\$ 674	\$ 6,206
2025		5,281	368	5,649
2026		3,045	142	3,187
2027		1,648	15	1,663
2028		182	3	185
Total payments				
required	\$	15,688	\$ 1,202	\$ 16,890

Future minimum lease (GASB No. 87) payments are as follows (in thousands):

		Principal	Interest	Total
Years ending September 30:	,			
2024	\$	2,170	\$ 204	\$ 2,374
2025		2,053	172	2,225
2026		2,004	139	2,143
2027		1,566	111	1,677
2028		1,486	83	1,569
2029-2065		3,666	141	3,807
Total payments				
required	\$	12,945	\$ 850	\$ 13,795

As of September 30, 2023, the unamortized value of right to use lease and SBITA assets included in capital assets, net in the statement of net position was \$27.8 million and the accumulated amortization on right to use lease and SBITA assets as of September 30, 2023 was \$9.9 million.

<u>Lessor Leases</u>: In connection with the adoption of GASB No. 87, Halifax Health recognized a lease receivable and a deferred inflow of resources for lease agreements in which Halifax Health was the lessor. Each lease provides for a monthly lease payment subject to a fixed escalation on the anniversary date of each agreement. Lease revenue related to lessor leases was \$2.8 million for the year ended September 30, 2023. Interest income on lessor leases was \$99,000 for the year ended September 30, 2023, the long-term rent receivable for leases was \$4.5 million.

Notes to Financial Statements

Note 12. Commitments and Contingencies (Continued)

Future principal and interest requirements to maturity for the rent receivables are as follows (in thousands):

	F	Principal	Interest	Total
Years ending September 30:				
2024	\$	1,793	\$ 82	\$ 1,875
2025		1,312	67	1,379
2026		664	56	720
2027		457	47	504
2028		384	42	426
2029-2065		1,677	305	1,982
Total payments				
required	\$	6,287	\$ 599	\$ 6,886

<u>Contingencies</u>: The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violations of these laws and regulations could result in significant fines and penalties, including repayments for patient services previously reimbursed.

Halifax Health is subject to various legal proceedings and claims, which are incidental to its normal business activities. In the opinion of Halifax Health's management, the ultimate liability with respect to these actions will not materially affect the operations or net position of Halifax Health.

Note 13. Concentrations of Credit Risk

The Medical Center and Hospice grant credit without collateral to its patients, most of who are local residents that are insured under third-party payor agreements. The mix of net receivables from patients and third-party payors at September 30, 2023, was as follows:

Medicare	13%
Medicaid	5%
Other third-party payors	81%
Self-pay patients	1%
Total	100%

Note 14. Joint Ventures

EVHS has a 50% equity interest in a joint venture to operate East Central Florida Outpatient Imaging, LLC (ECFOI). During the year ended September 30, 2023, EVHS received distributions of \$2.0 million from ECFOI and recognized its proportionate share of ECFOI's net income or loss by adjusting its equity interest balance. At September 30, 2023, EVHS had \$1.5 million recorded as an equity interest in ECFOI that is included in other assets in the accompanying financial statements. ECFOI issues stand-alone financial statements.

Notes to Financial Statements

Note 14. Joint Ventures (Continued)


EVHS has a 50% equity interest in a joint venture to develop and operate outpatient facilities. At September 30, 2023, EVHS had \$2.3 million recorded as an equity interest that is included in other assets in the accompanying financial statements. During the year ended September 30, 2023, there were no distributions.

EVHS has a 50% equity interest in a joint venture to operate HB Rehabilitative Services, Inc. ("HB"). During the year ended September 30, 2023, EVHS received distributions of \$2.0 million from HB, and at September 30, 2023, EVHS had \$8.2 million recorded as an equity interest in HB that is included in other assets in the accompanying financial statements.

MCD and Brooks Halifax Rehabilitation Services, LLC, ("Brooks") entered into a joint venture agreement to provide outpatient rehabilitation clinics. MCD has a 50% equity interest in the joint venture to operate as HB Deltona Rehabilitative Services, LLC ("HBD"). During the year ended September 30, 2023, there were no distributions. MCD had \$263,000 recorded as an equity interest. HB does not issue stand-alone financial statements.

Note 15. Subsequent Events

Management has evaluated subsequent events through January 25, 2024, the date the financial statements were available to be issued.



Required Supplementary Information (Unaudited) Schedule of Changes in Net Pension Liability (In Thousands)

		Total Pension Liability, (a)	Plan Fiduciary Net Pension, (b)	Net Pension Liability, (a) - (b)
Balance, September 30, 2014	\$	311,814	\$ 207,198 \$	104,616
Service cost		2,776	-	2,776
Interest		20,547	-	20,547
Difference between expected and actual experience		(2,241)	-	(2,241)
Contributions—employer		-	20,000	(20,000)
Net investment income		-	12,954	(12,954)
Benefit payments		(15,077)	(15,077)	-
Plan administrative expenses		· -	(59)	59
Balance, September 30, 2015	. <u></u>	317,819	225,016	92,803
Service cost		4,282	· -	4,282
Interest		20,943	_	20,943
Difference between expected and actual experience and		-,-		-,-
assumption changes		(4,845)	_	(4,845)
Contributions—employer		-	15,218	(15,218)
Net investment income		_	(9,853)	9,853
Benefit payments		(15,355)	(15,355)	-
Plan administrative expenses		-	(115)	115
Balance, September 30, 2016		322,844	214,911	107,933
Service cost		4,441	-	4,441
Interest		21,234	_	21,234
Difference between expected and actual experience and		•		•
assumption changes		(2,804)	-	(2,804)
Contributions—employer		-	21,236	(21,236)
Net investment income		-	20,892	(20,892)
Benefit payments		(16,818)	(16,818)	-
Plan administrative expenses		-	(77)	77
Balance, September 30, 2017	. <u></u>	328,897	240,144	88,753
Service cost		3,770	-	3,770
Interest		21,776	_	21,776
Difference between expected and actual experience and				
assumption changes		1,387	-	1,387
Contributions—employer		-	21,060	(21,060)
Net investment income		-	25,668	(25,668)
Benefit payments		(20,439)	(20,439)	-
Plan administrative expenses		-	(74)	74
Balance, September 30, 2018		335,391	266,359	69,032
Service cost		3,311	· -	3,311
Interest		22,154	-	22,154
Difference between expected and actual experience and				
assumption changes		2,490	-	2,490
Contributions—employer		-	19,876	(19,876)
Net investment income		-	15,283	(15,283)
Benefit payments		(21,349)	(21,349)	-
Plan administrative expenses		-	(71)	71
Balance, September 30, 2019	\$	341,997	\$ 280,098 \$	61,899

(Continued)

Required Supplementary Information (Unaudited) Schedule of Changes in Net Pension Liability (Continued) (In Thousands)

	Total Pension Liability, (a)	Plan Fiduciary Net Pension, (b)	Net Pension Liability, (a) - (b)
Balance, September 30, 2019	\$ 341,997	\$ 280,098 \$	61,899
Service cost	2,769	-	2,769
Interest	22,596	-	22,596
Difference between expected and actual			
experience and assumption changes	13,430	-	13,430
Contributions—employer	-	19,500	(19,500)
Net investment income	-	(3,969)	3,969
Benefit payments	(20,359)	(20,359)	-
Plan administrative expenses	-	(68)	68
Balance, September 30, 2020	360,433	275,202	85,231
Service cost	2,133	, -	2,133
Interest	23,733	-	23,733
Difference between expected and actual	,		•
experience and assumption changes	2,266	(7,526)	9,792
Change of assumptions	87	-	87
Contributions—employer	_	23,472	(23,472)
Net investment income	_	19,420	(19,420)
Benefit payments	(22,296)	(22,296)	-
Plan administrative expenses	-	(107)	107
Balance, September 30, 2021	366,356	288,165	78,191
Service cost	1,809	-	1,809
Interest	24,071	-	24,071
Difference between expected and actual	,		•
experience and assumption changes	(4,216)	37,072	(41,288)
Change of assumptions	9,027	, -	9,027
Contributions—employer	, -	25,947	(25,947)
Net investment income	-	20,402	(20,402)
Benefit payments	(23,505)	(23,505)	-
Plan administrative expenses	-	(39)	39
Balance, September 30, 2022	373,542	348,042	25,500
Service cost	1,661	-	1,661
Interest	22,874	_	22,874
Difference between expected and actual experience	(8,950)	(58,769)	49,819
Change of assumptions	4,213	-	4,213
Contributions—employer	-	21,315	(21,315)
Net investment income	-	22,491	(22,491)
Benefit payments	(47,331)	(47,331)	-
Plan administrative expenses	- '	(41)	41
Balance, September 30, 2023	\$ 346,009	\$ 285,707 \$	60,302

Source: BPAS Actuarial and Pension Services.

Required Supplementary Information (Unaudited) Schedule of Funding Progress (In Thousands)

													Fiduciary Net	Net Pension
				Plan			Me	dical Center	I	Hospice			Position as a %	Liability
	То	tal Pension		Fiduciary	Ne	et Pension	Pro	oportionate	Pro	portionate	C	overed	of Net Pension	as a % of
Actuarial		Liability	Ν	let Position		Liability		Share		Share		Payroll	Liability	Covered
Valuation Date		(a)		(b)		(a-b)	(a-l	b) * 94.19%	(a-	b) * 5.81%		(c)	(b/a)	Payroll
October 1, 2021	\$	346,009	\$	285,707	\$	60,302	\$	56,798	\$	3,504	\$	18,233	83%	331%
October 1, 2020		373,542		348,042		25,500		24,018		1,482		21,589	93	118
October 1, 2019		366,356		288,165		78,191		72,030		6,161		23,098	79	339
October 1, 2018		360,433		275,202		85,231		78,515		6,716		26,858	76	317
October 1, 2017		341,997		280,098		61,899		59,000		2,899		32,092	82	193
October 1, 2016		335,391		266,359		69,032		65,145		3,887		33,515	79	206
October 1, 2015		328,897		240,144		88,753		83,756		4,997		38,361	73	231
October 1, 2014		322,844		214,911		107,933		101,856		6,077		42,387	67	255
October 1, 2013		317,819		225,016		92,803		87,578		5,225		43,613	71	213
October 1, 2012		311,814		207,198		104,616		98,726		5,890		46,960	66	223

Source: BPAS Actuarial and Pension Services.

Required Supplementary Information (Unaudited) Schedule of Actuarially Determined Contributions (In Thousands)

		ctuarially termined		ntributions ecognized	A Dete	ference of actuarially ermined and accognized	% Contributions Recognized to Contributions Actuarially		Covered	Contributions as a % of Covered
Actuarial	Cor	Contributions		During the year		ntributions	Determined	,		Payroll
Valuation Date		(a)		(b)		(a-b)	(b/a)		(c)	(b/c)
October 1, 2021	\$	16,600	\$	21,315	\$	(4,715)	128%	\$	18,233	117%
October 1, 2020		21,315		25,947		(4,632)	122		21,589	120
October 1, 2019		25,947		23,472		2,475	90		23,098	102
October 1, 2018		23,472		19,500		3,972	83		26,858	73
October 1, 2017		19,500		19,876		(376)	102		32,092	62
October 1, 2016		19,876		21,060		(1,184)	106		33,515	63
October 1, 2015		21,060		21,236		(176)	101		38,361	55
October 1, 2014		21,236		15,218		6,018	72		42,387	36
October 1, 2013		15,218		20,000		(4,782)	131		43,613	46
October 1, 2012		17,278		12,688		4,590	73		46,960	27

Source: BPAS Actuarial and Pension Services.

Note to Required Supplementary Information - Halifax Pension Plan (Unaudited)

Note 1. Key Assumptions

The information presented in the required supplemental schedules was determined as part of the actuarial valuations at the dates indicated. Additional information as of the latest actuarial valuation follows:

Valuation date October 1, 2022
Actuarial cost method Entry Age Normal, Level Percent of Pay
Amortization method 10 year, closed

Remaining amortization period Varies

Asset valuation method Market value

Actuarial assumptions:

Investment rate of return 6.375%
Projected salary increases NA
Cost-of-living adjustments 3.00%

Mortality Pri-2012 Mortality Table (Sex-Distinct), Scale MP-2021 Retirement age 62

These actuarial assumptions are based on the presumption that the Plan will continue. Should the Plan terminate, different actuarial assumptions and other factors might be applicable in determining the actuarial present value of accumulated Plan benefits. Also, changes in actuarial assumptions and methods may affect the amounts reported and information presented in the required supplemental schedules.

Since the last measurement date, September 30, 2022, the Plan updated its assumptions regarding the interest rates. The change in the Plan assumption from 6.50% to 6.375% resulted in an increase in the pension liability of approximately \$34.8 million at September 30, 2023.

In accordance with GASB Cod. Sec. Pe5, *Pension Plans – Defined Benefit*, Halifax Health is required to present 10 years of data in the required supplemental schedules; however only nine years of information is available since implementing GASB Statement No. 68 on October 1, 2014. Annual Plan Information will be added until the required 10 years is presented.

Required Supplementary Information (Unaudited) Schedule of Changes in Total Retiree HRA Plan Liability and Related Ratios (In Thousands)


			Υ	ears Ended	Sept	tember 30		
	2023	2022		2021		2020	2019	2018
Total Retiree HRA Plan liability								
Service cost	\$ 186	\$ 197	\$	213	\$	162	\$ 197	\$ 173
Interest	445	483		528		647	617	601
Changes of benefit terms	-	-		-		-	-	(559)
Differences between expected and actual experience	(356)	132		199		(76)	43	96
Changes of assumptions or other inputs	(3,923)	472		778		2,419	(1,255)	(1,949)
Benefit payments	(1,004)	(942)		(878)		(846)	(274)	(750)
Net change in total Retiree								
HRA Plan liability	(4,652)	342		840		2,306	(672)	(2,388)
Total Retiree HRA Plan liability—beginning	 20,649	20,307		19,467		17,161	17,833	20,221
Total Retiree HRA Plan liability—ending	\$ 15,997	\$ 20,649	\$	20,307	\$	19,467	\$ 17,161	\$ 17,833
Covered-employee payroll	\$ 18,232	\$ 21,589	\$	23,098	\$	32,044	\$ 32,092	\$ 33,468
Total Retiree HRA Plan liability as a percentage of covered-employee payroll	87.74%	95.64%		87.92%		60.62%	53.48%	53.28%
Changes of assumptions or other inputs reflect a change in the discount rate of:	4.40%	2.19%		2.41%		2.75%	3.83%	3.50%

This schedule is presented to illustrate the requirement to show information for 10 years. However, only six years of information are available since implementing GASB No. 75 at October 1, 2017. Annual plan information will be added until the required 10 years is presented.

Required Supplementary Information (Unaudited) Schedule of Changes in Total Retiree Medical Plan Liability and Related Ratios (In Thousands)

			Υ	ears Ended	Sep	tember 30		
	 2023	2022		2021		2020	2019	2018
Total Retiree Medical Plan liability								
Service cost	\$ 2	\$ 2	\$	4	\$	2	\$ 3	\$ 170
Interest	20	34		51		80	89	205
Changes of benefit terms	-	-		-		-	-	(5,085)
Differences between expected and								
actual experience	(105)	(308)		(132)		5	-	1,510
Changes of assumptions or other inputs	9	17		(35)		126	(58)	(530)
Benefit payments	(197)	(300)		(392)		(454)	(519)	(320)
Net change in total Retiree								
Medical Plan liability	(271)	(555)		(504)		(241)	(485)	(4,050)
Total Retiree Medical Plan liability—beginning	 1,005	1,560		2,064		2,305	2,790	6,840
Total Retiree Medical Plan liability—ending	\$ 734	\$ 1,005	\$	1,560	\$	2,064	\$ 2,305	\$ 2,790
Covered-employee payroll	\$ 18,232	\$ 21,589	\$	23,098	\$	32,044	\$ 32,092	\$ 33,468
Total Retiree Medical Plan liability as a								
percentage of covered-employee payroll	4.03%	4.66%		6.44%		6.44%	7.18%	8.34%
Changes of assumptions or other inputs reflect								
a change in the discount rate of:	4.40%	2.19%		2.41%		2.75%	3.83%	3.50%

This schedule is presented to illustrate the requirement to show information for 10 years. However, only six years of information are available since implementing GASB No. 75 at October 1, 2017. Annual plan information will be added until the required 10 years is presented.



Supplementary Information
Schedule of Net Position—Obligated Group
September 30, 2023
(In Thousands)

Assets and Deferred Outfle	ows
----------------------------	-----

Assets and Deferred Outflows Current Assets:		
Cash and cash equivalents	\$	131,240
Investments	Y	181,099
Current assets whose use is limited—Trustee-held		,
self-insurance funds		229
Accounts receivable, patients, net of estimated uncollectibles of \$73,520		73,769
Inventories		18,917
Current portion of rent receivable		1,438
Other current assets		32,127
Total current assets		438,819
Noncurrent Assets Whose Use is Limited:		
Board-designated funded depreciation		26,734
Depreciable capital assets, net		212,067
Nondepreciable capital assets		97,107
Right to use assets, net		35,330
Investment in affiliates		196,223
Rent receivable, less current portion		4,683
Other assets		17,268
Total assets		1,028,231
Deferred Outflows:		
Interest rate swap		8,310
Pension, contribution after measurement date		15,636
Pension, other		30,596
Deferred outflows related to other postemployment benefits		1,104
Loss on refunding of debt, net		11,198
Total deferred outflows		66,844
Total assets and deferred outflows	\$	1,095,075

(Continued)

Net Position:

Unrestricted

Net investment in capital assets

Total net position

Total liabilities, deferred inflows and net position

Supplementary Information Schedule of Net Position—Obligated Group (Continued) September 30, 2023 (In Thousands)

Liabilities, Deferred Inflows and Net Position	
Current Liabilities:	
Accounts payable and accrued liabilities	\$ 116,786
Accrued payroll and personal leave time	29,091
Current portion of accrued self-insurance liability	4,285
Current portion of long-term debt	7,610
Current portion of lease liabilities	4,327
Current portion of SBITA liabilities	5,269
Interest payable on long-term debt	3,638
Other current liabilities	2,824
Total current liabilities	 173,830
Noncurrent Liabilities:	
Long-term debt, less current portion	309,210
Long-term lease liabilities, less current portion	17,100
Long-term SBITA liabilities, less current portion	9,732
Premium on long-term debt, net	8,434
Net pension liability	56,799
Other postemployment benefits liability	15,759
Accrued self-insurance liability, less current portion	8,465
Other liabilities	10,654
Long-term value of interest rate swap	8,310
Total liabilities	 618,293
Deferred inflows related to leases	5,970
Deferred inflows related to other post employment benefits	235
Total liabilities and deferred inflows	 624,498

28,535

442,042

470,577

\$ 1,095,075

Supplementary Information Schedule of Revenues, Expenses and Changes in Net Position—Obligated Group Year Ended September 30, 2023 (In Thousands)

Net patient service revenue, before provision for bad debts \$ 678,587 Provision for bad debts (48,004) Net patient service revenue 630,583 Ad valorem tax revenue 20,640 Other revenue 20,730 Total operating revenues 671,953 Operating Expenses: 319,710 Sularies and benefits 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 26,012 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 <th>Operating Revenues:</th> <th></th> <th></th>	Operating Revenues:		
Net patient service revenue 630,583 Ad valorem tax revenue 20,640 Other revenue 20,730 Total operating revenues 671,953 Operating Expenses: 319,710 Salaries and benefits 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position	Net patient service revenue, before provision for bad debts	\$	678,587
Ad valorem tax revenue 20,430 Other revenue 20,730 Total operating revenues 671,953 Operating Expenses: 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Provision for bad debts		(48,004)
Other revenue 20,730 Total operating revenues 671,953 Operating Expenses: 319,710 Sataries and benefits 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Net patient service revenue		630,583
Total operating revenues 671,953 Operating Expenses: 319,710 Salaries and benefits 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Ad valorem tax revenue		20,640
Operating Expenses: 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Other revenue		20,730
Salaries and benefits 319,710 Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Total operating revenues		671,953
Supplies 136,631 Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Operating Expenses:		
Purchased services 117,755 Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Salaries and benefits		319,710
Depreciation and amortization 28,829 Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Supplies		136,631
Ad valorem tax-related expenses 6,794 Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Purchased services		117,755
Leases and rentals 2,680 Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Depreciation and amortization		28,829
Other 26,012 Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): *** Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Ad valorem tax-related expenses		6,794
Total operating expenses 638,411 Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Leases and rentals		2,680
Income from operations 33,542 Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position	Other		26,012
Nonoperating Revenues (Expenses): (14,137) Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: 8eginning net position 414,226	Total operating expenses		638,411
Interest expense (14,137) Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: 8eginning net position 414,226	Income from operations		33,542
Investment income, net 10,046 Donation revenue 361 Nonoperating gains, net 2,696 Income from affiliates 11,843 Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: 8eginning net position 414,226	Nonoperating Revenues (Expenses):		
Donation revenue361Nonoperating gains, net2,696Income from affiliates11,843Total nonoperating revenues, net10,809Excess of revenue over expenses44,351Other changes in net position of affiliate12,000Increase in net position56,351Net Position: Beginning net position414,226	Interest expense		(14,137)
Nonoperating gains, net Income from affiliates Total nonoperating revenues, net Excess of revenue over expenses Other changes in net position of affiliate Increase in net position Increase in net position Seginning net position 414,226	Investment income, net		10,046
Income from affiliates Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Donation revenue		361
Total nonoperating revenues, net 10,809 Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Nonoperating gains, net		2,696
Excess of revenue over expenses 44,351 Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Income from affiliates		11,843
Other changes in net position of affiliate 12,000 Increase in net position 56,351 Net Position: Beginning net position 414,226	Total nonoperating revenues, net	•	10,809
Increase in net position 56,351 Net Position: Beginning net position 414,226	Excess of revenue over expenses		44,351
Net Position: Beginning net position 414,226	Other changes in net position of affiliate		12,000
Beginning net position 414,226	Increase in net position		56,351
	Net Position:		
End of year \$ 470,577	Beginning net position		414,226
	End of year	\$	470,577

Supplementary Information
Note to Schedules – Obligated Group

Note 1. Summary of Significant Accounting Policies

Obligated Group: The members of the Obligated Group are the Medical Center and Holdings. In accordance with generally accepted accounting principles, certain component units are blended with the accounts of the Medical Center in the Obligated Group financial information, including EVHS, Staffing, HHCSI and PBFS. In addition, Hospice, VHN, Foundation, MCD and HMS are accounted for under the equity method in the Obligated Group financial information. The Medical Center has an equity interest in these entities, which are expected to produce income, appreciation in value, or other economic benefit. The net investment in capital assets and unrestricted components of the net position of the affiliates are included in equity interest in affiliates on the schedule of net position and income from affiliates is separately disclosed on the schedule of revenues, expenses, and changes in net position. In accordance with the MTI, the Obligated Group does not have ownership rights to the affiliates' restricted component of net position; therefore, they are excluded from the equity interest in affiliates.

The affiliates are not members of the Obligated Group and are not required to pay operating expenses or debt service of the Obligated Group. Except as may be requested by the Medical Center or Hospice, subject to certain limitations, to avoid or remedy a payment or covenant default, affiliates are not required to make any payments with respect to the outstanding indebtedness of the Medical Center or the Obligated Group.

Supplementary Information
Condensed Combining Schedule of Revenues, Expenses and Changes in Net Position—Florida Hospital Uniform Reporting System
Year Ended September 30, 2023
(In Thousands)

	Operating Entities					_											
			Staffing					_							Halifax Health		
			Medical				Total					Subtotal of	Subtotal of	Medical	Before		
	Medical		Center				Medical			ting Entities		Nonoperating			Intercompany	Intercompany	
	Center	Holdings	Division	PBFS	HHCSI	EVHS	Center	Hospice	VHN	Foundation	HMS	Entities	Medical Center	Deltona	Eliminations	Eliminations	Halifax Health
Operating revenues	\$ 658,783	\$ 1,807	\$ -	\$ -	\$ 2,658	\$ 8,705	\$ 671,953	\$ 57,619	\$ 1,130	\$ 7,773	\$ 5,152	\$ 71,674	\$ 743,627	\$ 47,164	\$ 790,791	\$ (4,334)	\$ 786,457
Operating expenses, before depreciation and																	
amortization	275,980	363	295,530	30,410	3,263	4,036	609,582	51,325	1,000	899	1,007	54,231	663,813	49,387	713,200	(354)	712,846
Depreciation and amortization	28,000	556	-	-	246	27	28,829	1,124	-	-	1,922	3,046	31,875	6,783	38,658	(3,980)	
Total operating expenses	303,980	919	295,530	30,410	3,509	4,063	638,411	52,449	1,000	899	2,929	57,277	695,688	56,170	751,858	(4,334)	747,524
Income (loss) from operations	354,803	888	(295,530)	(30,410)	(851)	4,642	33,542	5,170	130	6,874	2,223	14,397	47,939	(9,006)	38,933	-	38,933
Non operating revenues (expenses)	(331,999)	5,025	295,530	30,410	-	-	(1,034)	11,081	-	-	505	11,586	10,552	(5,134)	5,418	-	5,418
Contributions		-	-	-	-	-	-	-	-	-	-	-	-	12,000	12,000	-	12,000
Increase (decrease) in net position	\$ 22,804	\$ 5,913	\$ -	\$ -	\$ (851)	\$ 4,642	\$ 32,508	\$ 16,251	\$ 130	\$ 6,874	\$ 2,728	\$ 25,983	\$ 58,491	\$ (2,140)	\$ 56,351	\$ -	\$ 56,351

Halifax Staffing provides employees to staff and manage the Medical Center and MCD. Expenses for these divisions are separately reported in the columns above..

Compliance Report September 30, 2023

Contents

Report on internal control over financial reporting and on compliance and other matters based on an audit of financial statements performed in accordance	
with Government Auditing Standards	1-2
Report on compliance for the major federal program; report on internal control over compliance; and report on schedule of expenditures of federal awards	
required by the Uniform Guidance	3-5
Schedule of expenditures of federal awards	6
Notes to schedule of expenditures of federal awards	7
Schedule of findings and questioned costs	8
Summary schedule of prior audit findings	9



Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

RSM US LLP

Independent Auditor's Report

Honorable Commissioners of the Board Halifax Hospital Medical Center d/b/a Halifax Health

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of the business-type activities and the aggregate remaining fund information of Halifax Hospital Medical Center d/b/a Halifax Health ("Halifax Health"), which comprise Halifax Health's statement of net position as of September 30, 2023, and the related statements of revenue, expenses and changes in net position and statement of cash flows for the year then ended, and the related notes to the financial statements, which collectively comprise Halifax Health's basic financial statements, and have issued our report thereon dated January 25, 2024. Other auditors audited the financial statements of Halifax Health's fiduciary activities as described in our report on Halifax Health's financial statements. This report does not include the results of other auditors' testing of internal control over compliance that is reported on separately by those auditors.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the basic financial statements, we considered Halifax Health's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Halifax Health's internal control. Accordingly, we do not express an opinion on the effectiveness of Halifax Health's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Halifax Health's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

RSM US LLP

Davenport, Iowa January 25, 2024



Report on Compliance for the Major Federal Program; Report on Internal Control Over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance **RSM US LLP**

Independent Auditor's Report

Honorable Commissioners of the Board Halifax Hospital Medical Center d/b/a Halifax Health

Report on Compliance for the Major Federal Program

Opinion on the Major Federal Program

We have audited Halifax Health's compliance with the types of compliance requirements identified as subject to audit in the OMB Compliance Supplement that could have a direct and material effect on Halifax Health's major federal program for the year ended September 30, 2023. Halifax Health's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, Halifax Health complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended September 30, 2023.

Basis for Opinion on the Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Halifax Health and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance the major federal program. Our audit does not provide a legal determination of Halifax Health's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Halifax Health's federal programs.

THE POWER OF BEING UNDERSTOOD AUDIT | TAX | CONSULTING

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Halifax Health's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Halifax Health's compliance with the requirements of the major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design
 and perform audit procedures responsive to those risks. Such procedures include examining, on a
 test basis, evidence regarding Halifax Health's compliance with the compliance requirements referred
 to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Halifax Health's internal control over compliance relevant to the audit in
 order to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of
 expressing an opinion on the effectiveness of Halifax Health's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance We have audited the basic financial statements of Halifax Health as of and for the year ended September 30, 2023, and have issued our report thereon dated January 25, 2024, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the basic financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the basic financial statements. The information has been subjected to the auditing procedures applied in the audit of the basic financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the basic financial statements or to the basic financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the basic financial statements as a whole.

RSM US LLP

Davenport, Iowa January 25, 2024

Schedule of Expenditures of Federal Awards Year Ended September 30, 2023

	Assistance	Grantor's	Passed Through to				
	Listing	Identifying			Federal		
Federal Grantor/Pass–Through Grantor/Program Title	Number	Number	Subrec	ipients	Expenditures		
U.S. Department of Health and Human Services:							
COVID-19: Provider Relief Fund and American Rescue							
Plan (ARP) Rural Distribution	93.498	N/A	\$	-	\$	5,711,034	
Passed Through Lutheran Services of Florida:							
Block Grants for Community Mental Health Services	93.958	59-2198911		-		288,090	
Total expenditures of federal awards			\$	_	\$	5,999,124	

See notes to schedule of expenditures of federal awards.

Notes to the Schedule of Expenditures of Federal Awards Year Ended September 30, 2023

Note 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of Halifax Hospital Medical Center d/b/a Halifax Health (Halifax Health) under programs of the federal government for the year ended September 30, 2023. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the basic financial statements.

For purposes of the Schedule, federal awards include all federal assistance entered into directly between Halifax Health and the federal government and sub-awards from nonfederal organizations made under federally sponsored agreements. The Schedule does not include payments received under Medicare and Medicaid reimbursement programs. Because the Schedule presents only a selected portion of the activities of Halifax Health, it is not intended to, and does not, present the net position, changes in net position or cash flows of Halifax Health.

Note 2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

Note 3. Indirect Cost Rate

Halifax Health has elected not to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Note 4. Noncash Assistance, Insurance, Loans and Loan Guarantees Outstanding

Halifax Health did not receive any noncash assistance during the year ended September 30, 2023. There were no federal awards expended for insurance or any loans or loan guarantees outstanding as of September 30, 2023.

Note 5. Provider Relief Fund

Under the terms and conditions of the Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution program (PRF) (ALN 93.498), Halifax Health is required to report COVID-19 related expenses and lost revenue to the U.S. Department of Health and Human Services (HHS). Guidance from HHS has required the reporting of the COVID-19 related expenses and lost revenue in certain reporting periods based on when the funds were received.

The September 30, 2023 Schedule includes PRF expenditures of approximately \$5,711,000. Distributions of \$5,711,034 were received by Halifax Health from July 1, 2021 to December 31, 2021.

Halifax Health recognized all of the \$5,711,034 distribution received as revenue in its September 30, 2022 financial statements, as the terms and conditions of the PRF were satisfied. HHS requires PRF amounts received between July 1, 2021 and June 30, 2022 to be reported on the September 30, 2023 Schedule rather than the September 30, 2022 Schedule.

Schedule of Findings and Questioned Costs For the Year Ended September 30, 2023

Section I. Summary of Auditor's Results **Financial Statements:** Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified Internal control over financial reporting: Material weakness(es) identified? Yes X No Significant deficiency(ies) identified? Yes X None Reported Noncompliance material to financial statements noted? Yes X No **Federal Awards:** Internal control over major programs: Material weakness(es) identified? Yes X No Significant deficiency(ies) identified? X None Reported Yes Type of auditor's report issued on compliance for major Unmodified federal programs: Any audit findings disclosed that are required to be reported in accordance with section 2 CFR 200.516(a)? Yes X No Identification of major federal programs: **Assistance Listing Numbers** Name of Federal Program or Cluster 93.498 COVID-19: Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution Dollar threshold used to distinguish between type A and type B programs \$750,000 Auditee qualified as low-risk auditee? X Yes No Section II. Financial Statement Findings No matters were reported Section III. Federal Award Findings and Questioned Costs

otion iii. 1 odordi / tirdi a 1 iiidii igo diid Quootioiiod

No matters were reported

Summary Schedule of Prior Audit Findings For the Year Ended September 30, 2023

There were no prior audit findings.